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Abstract
With the evolution of the high-trough-put screening (HTS) methods it is now possible
to screen up to 100 000 pharmaceutical compounds each week and thus the amount
of possible new active pharmaceutical ingredient (API) grow every week [1,2]. Because
of the fact that nearly half of the new API found today with the help of HTS have a
low water solubility, electrohydrodynamic atomization (EHDA) can help to encapsulate
these drugs for better bioavailability [3,4].
As model drug Ibuprofen was used in this thesis, because Ibuprofen is one of the most
used non-steroidal anti-inflammatory drugs (NSAIDs) and has a low water solubility.
To enhance the bioavailability of Ibuprofen an encapsulation of it into nanoparticles
and -fibers with core-shell architecture was done and the encapsulation and releasing
efficiency was investigated.
Three different and already well researched polymers, poly(-caprolactone) (PCL),
poly(vinyl alcohol) (PVA) and poly(vinyl pyrrolidone) (PVP), were used to encapsulate
Ibuprofen into coaxial nanofibers.
With PVA fibers a theoretical drug loading of 64 wt% was achieved and after 7 h 23%
of the theoretical Ibuprofen amount was released, with a burst release of 20% after one
hour.
The PVP fibers could be loaded with 22 wt% of Ibuprofen and they released all of the,
from the flow rates calculated, Ibuprofen after 20 h, so they showed a high encapsulation
efficiency and a slow release rate, with only releasing 28% after one hour.
With PCL as shell polymer two different types of coaxial fibers were produced, one
with a core only made of Ibuprofen and the other with a PVP and Ibuprofen core. The
first one released 100% of the theoretical Ibuprofen amount after 20 h with burst releases
of 66% to 76% after one hour and drug loadings of 30 wt% to 50 wt% Ibuprofen into the
fibers, in dependence of the PCL concentration used. The latter one had drug loadings
of 19 wt% to 26 wt%, also in dependence of the used PCL concentration, and releases of
77% to 89% after 20 h and after one hour burst releases of 26% to 77% were achieved.
With the PCL fibers and the PVP fibers one could achieve a covering of the therapeu-
tic window of Ibuprofen over a time span of 8 h, in comparison to 2 h with commercially
available tablets [5]. Furthermore with the combination of the fast releasing PVA fibers
and the slowly releasing PCL one could also cover the therapeutic window from the first
hour on.
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Zusammenfassung
Mit der Entwicklung der Hochdurchsatz-Screening (HTS) Methode ist es nun möglich
wöchentlich bis zu 100 000 neuer pharmazeutischer Komponenten zu überprüfen und
infolgedessen steigt der Anteil an neuen Arzneistoffen (active pharmaceutical ingre-
dients, API) jede Woche [1,2]. Weil annähernd die Hälfte dieser heutzutage gefunde-
nen API eine schlechte Wasserlöslichkeit aufweisen, kann die elektrohydrodynamische
Atomisierung (EHDA) dabei helfen diese Arzneistoffe zu verkapseln und dadurch ihre
Bioverfügbarkeit zu verbessern [3,4].
Ibuprofen wurde in dieser Arbeit als Modelarzneistoff verwendet, da Ibuprofen eines
der meist verwendeten nichtsteroidalen Antirheumatika (NSAR) ist und eine schlechte
Wasserlöslichkeit aufweist. Um die Bioverfügbarkeit zu erhöhen wurde eine Verkap-
slung in Nanopartikeln und -fasern mit einer Kern-Schalen Architektur durchgeführt
und anschliessend wurde die Effizient der Verkapslung und der Freisetzung untersucht.
Drei verschiedene Polymere, Poly(-caprolacton) (PCL), Poly(vinyl alkohol) (PVA)
und Poly(vinyl pyrrolidon) (PVP) wurden für die Verkapselung von Ibuprofen in coax-
ialen Fasern verwendet.
Mit PVA wurde eine theoretische Arzneistoff-Beladung von 64 wt% erreicht und nach
7 h wurden 23% des theoretischen Ibuprofen Gehaltes freigesetzt, mit einer Startfreiset-
zung von 20% nach einer Stunde.
Die PVP Fasern konnten mit 22 wt% Ibuprofen beladen werden und setzten das
gesamte, aus den Flussraten berechnete, Ibuprofen nach 20 h frei. Dies lässt auf eine
hohe Verkapselungseffizienz schliessen und ebenso eine langsame Freisetzung, mit nur
28% nach einer Stunde.
Mit PCL als Polymer für die Hülle wurden zwei verschiedene Typen von coaxialen
Fasern hergestellt, die eine mit einem Kern nur aus Ibuprofen bestehend und die andere
mit einem Kern aus PVP und Ibuprofen. Der erste Typ setzte 100% des theoretischen
Ibuprofen Gehaltes nach 20 h frei mit einer Startfreisetzung von 66% bis 76% nach einer
Stunde und einer Medikamentenbeladung von 30 wt% bis 50 wt% Ibuprofen in den
Fasern, je nach benutzter Konzentration von PCL. Der letztere Typ hatte eine Medika-
mentenbeladung von 19 wt% bis 26 wt%, ebenfalls in Abhängigkeit der benutzten PCL
Konzentration, und erreichte eine Freisetzung von 77% bis 89% nach 20 h und bereits
nach einer Stunde eine Freisetzungsrate von 26% bis 77%.
Mit den PCL Fasern und den PVP Fasern konnte eine Abdeckung des therapeutischen
Fensters von Ibuprofen über eine Zeitspanne von 8 h erreicht werden, im Vergleich zu
2 h mit kommerziell erhältlichen Ibuprofen Tabletten [5]. Zudem kann mit einer Kom-
bination aus dem schnell freisetzenden PVA und dem langsam freisetzenden PCL eine
Abdeckung ab der ersten Stunde gewährleistet werden.
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On ne voit bien qu’avec le cœur.
L’essentiel est invisible pour les yeux.
Antoine de Saint-Exupéry [6]
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1. Introduction
The transportation of an API to the action site and the capability to enhance its bioavail-
ability is the reason for the increasing focus on drug delivery system (DDS) in the phar-
maceutical research. On the one hand DDS can help with the pharmacokinetics (PK),
i.e. the transportation and the release of the API into the human body, and on the other
hand it gives the possibility to formulate API with low water solubility, which were
found by HTS.
1.1. Personalized medicine
After the successful termination of the Human Genome Project in 2003 the research and
development of medicinal drugs has been shifted more in the direction of personalized
medicine [7,8]. With the decoding of the human genome the patient could be subdivided
in different groups which then can undergo individual therapies and would get differ-
ent drugs [9]. But the genome is not the only indicator for dividing people into different
groups, in recent years the research of so called biomarkers also helps in partitioning
patients [10]. In Figure 1 the difference between the conventional treatment and personal-
ized medicine, which is possible thanks to the research of the recent years, is shown [11].
The patient are split in different treatment groups in dependence of the response on
a specific API. So the term personalized medicine or personalized health care does not
mean, that there is a drug or therapy for each and every patient, but that the best possible
way of treatment based on the genome and biomarkers of the patient is used.
Figure 1: Difference between the conventional treatment and the personalized medicine. The
patients are divided in different treatment groups according to their genetic character-
istics [11].
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One resource used in the personalized medicine is the so called DDS. With the DDS
it is possible to transport the API to the desired active site in the human body. For such
drugs the formulation plays an important role, because the formulation decides, where
the API will be released [12]. Furthermore the formulation can regulate how fast the API
is released in the body, which can be shown in a so called drug release profile [13].
1.2. High throughput screening
Another reason why the formulation gets more and more an important role in the man-
ufacturing of drugs is the evolution of so called HTS methods. The HTS concept was
first mentioned in the years between 1984 and 1995 and then the application came in
the year 2000 [1]. The reason for the implementation of the HTS method came with a
project of the Pfizer Molecular Genetics Group, which had to construct a Streptomycete
library. With this project they had the challenge to identify up to 10 000 clones of this
bacteria. Until this project the normal capacity for screening was about 200 samples
per week, which would take the group way too long to analyze the desired 100 000
clones. With the help of automated processes and 96-well plates they could measure up
to 10 000 samples per week. The screening stage is the first stage in the development of
a new drug, as shown in Figure 2. Furthermore the usage of HTS contributes to savings
of nearly a year and about 150 millions dollars during the development of a new drug,
which can take 12 to 15 years and cost up to 1 billion dollar [14,15]. So now with the
advances in the HTS and the screening of more than 100 000 compounds each week the
bottleneck of the screening stage in the drug development has changed from the screen-
ing of the start compounds to the absorption, distribution, metabolism, and excretion -
toxicity (ADMET) part, stage 2 [2].
Figure 2: Illustration of the amount of compounds in the different stages of a drug development.
With the help of HTS the first stage can be screened faster, reproduced from [16].
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With the help of a appropriate DDS the amount of compounds which would go from
the first stage to the second could increase and also the ADMET research time could be
decreased.
One method which was investigated in the last years and which will also be used in
this thesis is the formulation with the help of EHDA, which is often divided in electro-
spraying and electrospinning [17–19]. These methods and other methods for DDS will be
explained more in the next chapter.
1.3. Motivation and scope of this thesis
In this thesis the model drug used was Ibuprofen, which structure is shown in Figure 3.
Ibuprofen is a NSAID derived from propionic acid [20]. Ibuprofen is widely used and in
the US nearly as many people use Ibuprofen as they are using Aspirin [21]. Ibuprofen is
a hydrophobic molecule and thus the formulation is complicated and would be easier
when encapsulated in a suited polymer [20,22].
CH3
H3C
CH3
O
OH
Figure 3: Molecular Structure of Ibuprofen.
The main task in this work can be described in three parts:
1. Encapsulate Ibuprofen either in a suitable biopolymer like pectin or ethyl cellulose
or in a food-grade polymer like PVA or PCL. The produced nanoparticles and -
fibers should then be characterized using SEM and other appropriate analysing
methods.
2. Research if and how the change of parameter influence the morphology and size
of the produced nanoparticles and -fibers.
3. To determine the encapsulation efficency with the help of release studies, UV and
HPLC. The drug loading should be around 20 % and the release of the drug from
the polymer in a simulated in vivo environment will be compare to the release of
a commercially available Ibuprofen tablet.
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2. Theoretical background
2.1. Drug delivery systems
As mentioned in the introduction, DDS can improve the pharmacological properties of
conventional drugs [23]. They can do this with the help of lipids and polymers, which
encapsulates the drug. The aim of the DDS is to change the so called PK and the
biodistribution (BD). Because of the fact that the DDS can not carry the same amount
of every drug, the drug has to be more potent the fewer molecules a DDS can carry.
This is needed to reach the therapeutic window of a drug [24]. A DDS will release a drug
from its container in a time dependent order, which means, that a lower distribution is
found in the body, which can also reduce the side effects [25].
To find a good combination between a drug and a DDS there are a few questions,
which had to be answered first:
• Will the drug still be functional once it is incorporated in the DDS or will there
be chemical bonds, that inhibit the drug?
• Will the DDS help to stabilize the drug long enough to reach the targeted area?
• Will the drug stay in the DDS until the targeted area is reached?
• Will the drug be released once the targeted area is reached or will it stay in the
DDS?
If the drug is already on the market or has undergone some clinical studies one can
compare the results of them with the results of the drug within a DDS to find the answers
of these questions without doing all the experiments again. For example, if the drug is
released fast from the container, then one can assume, that the PK and the BD of the
DDS will be the same as for the free drug and that the container only serves as vessel
for the drug to reach the desired area in the human body. On the other end, if the drug is
released slowly from the container then the PK and BD of the DDS will be the same as
the ones from the container, but most of the DDS will be in between these two extremes,
so the PK and BD of the DDS will be a combination of the PK and the BD from the
container and the free drug [26].
Because one aim of the DDS is to diminish the toxicity of the free drug most of the
DDS will use polymers or lipids which are not toxic and also biodegradable, so that the
DDS will not be toxic for the human body.
One of the disadvantages of a DDS is the problem with intellectual property (IP),
because one has to protect the drug, the container and also the system of both together.
This results in a higher amount of work for the IP-department, but can also lead to an
advantage when trying to patent an already protected drug.
For a DDS to become the most used application system of a drug, there has to made
some progress in the triggered-release systems and also in the routing of the DDS to the
target area in the human body.
Table 1 shows a summary of the advantages of a DDS compared to the free drugs [23].
There has already been a lot of research done in the area of targeted and also of triggered
DDS. The encapsulation of Ibuprofen, which has been done in this thesis, would help to
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Table 1: Non-ideal properties of drugs and their therapeutic implications, adapted from Allen and Cullis [23].
Problem Implication Effect of DDS
Poor solubility Hydrophobic drugs may precipitate in aqueous
media. Toxicities are associated with the use of
excipients such as Cremphor.
DDS such as lipid micelles or liposomes pro-
vide both hydrophilic and hydrophobic environ-
ments, enhancing drug solubility.
Tissue damage Accidentally extravasation of cytotoxic drugs
leads to tissue damage, e.g., tissue necrosis.
Regulated drug release from the DDS can re-
duce or eliminate tissue damage on accidental
extravasation.
Rapid breakdown of the
drug in vivo
Loss of activity of the drug follows administra-
tion, e.g., loss of activity at physiological pH.
DDS protects the drug from premature degrada-
tion and functions as a sustained release system.
Lower doses of drug are required.
Unfavorable pharma-
cokinetics
Drug is cleared too rapidly, by the kidney, for
example, requiring high doses or continuous in-
fusion.
DDS can substantially alter the PK of the drug
and reduce clearance. Rapid renal clearance of
small molecules is avoided.
Poor biodistribution Drugs that have widespread distribution in the
body can affect normal tissues, resulting in
dose-limiting side effects, such as the cardiac
toxicity.
The particulate nature of DDS lowers the vol-
ume of distribution and helps to reduce side ef-
fects in sensitive, nontarget tissues.
Lack of selectivity for
target tissues
Distribution of the drug to normal tissues leads
to side effects that restrict the amount of drug
that can be administered. Low concentrations of
drugs in target tissues will result in suboptimal
therapeutic effects.
DDS can increase drug concentrations in dis-
eased tissues such as tumors by the EPR effect.
Ligand-mediated targeting of the DDS can fur-
ther improve drug specificity.
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solve the poor solubility of Ibuprofen and also, when using a DDS with a slow release
profile it can help to enhance the PK and the activity of Ibuprofen in vivo.
One of the biggest challenges in creating a functional DDS is the controlled release,
once the DDS has reached its targeted area. Furthermore the DDS has to release the drug
in a time dependent matter and not just all in once, this to keep the therapeutic range
as long as possible. Such systems, which can release the drug once reached the desired
area, are called triggered-release systems. For the system to work it must be possible to
trigger the release of the API. If it is possible to regulate the stimulus for the release from
outside, this results in a more targeted way of setting the API free. This can be done over
a long time with impulses, e.g. for insulin, or over a short time but constantly, e.g. for an
anesthetic [27]. The release can be triggered either through a closed-loop or an open-loop
delivery system [28]. A closed-loop system describes a system in which the drug will be
released due to changes in the local environment, like pH [29–32] or temperature [33,34]. A
closed loop in contrast is a system, which can be triggered through an external stimuli
such as temperature, magnetic field [35,36], light [37–39], radio-frequency [40,41], lasers [42–44],
a NIR-pulse [45–47] or ultrasound [48], respectively [23,49]. The temperature can be both,
open-loop and closed-loop, because it can react due to differences between human cells
or it can change due to external changes of the temperature.
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2.2. Electrohydrodynamic atomization
The encapsulation of Ibuprofen in this thesis was done with the help of EHDA. For
this either electrospun fibers or electrosprayed particles were produced in a core-shell
architecture with Ibuprofen in its core and a shell made out of PCL, PVP or PVA. The
main difference of eletrospraying and electrospinning lies in the concentration of the
used solution, as is shown in Figure 4.
Figure 4: The figure illustrates the effect of the concentration, the flow rate and the voltage on
EHDA [50]. The concentration is the main effect on whether one gets beads or fibers
when working with a solution, low concetration leading to beads and high concentra-
tion to fibers, respectively.
2.2.1. Theoretical point of view
Richard Feynman held a talk in the year of 1959 with the title "There’s Plenty of Room
at the Bottom" to the American Physical Society [51]. In this talk he envisioned the pos-
sibility to work in the atomic scale and to modify molecules and atoms. Years later, this
field of work was named Nanotechnology, because of the scale, in which most of the
work is done. In the present day one has two ways to work in the field of nanotech-
nology, "bottom-up" and "top-down" [52]. In the latter approach one starts with a bulk
material and then through milling, etching or lithography works down to the nanoscale,
which means, that at least one dimension of the material is smaller than 100 nm [53]. The
"top-down" approach will not be discussed more deeply in this thesis, due to the fact,
that the approach used in this thesis is the "bottom-up". For this approach one stars with
elementary components, like molecules or atoms and forms them together to nanostruc-
ture. One possible way to do this is by using EHDA or more precisely electrospinning
and electrospraying.
Even if the application of electrospinning and electrospraying gained in importance
for research in the last 20 years, as can be seen by the number of publications with the
keyword "electrospinning" in Figure 5, the basic concept was already known a long time
ago [54].
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Figure 5: Amount of publications with keyword "electrospinning" per year starting from 1990
to 2017 (until july 2017) from Sci-finder. Adapted from Greiner and Wendorff [55].
The first to notice the effect of electricity on water was Gilbert [56] in 1600, when
he found out, that a water drop on a surface is transformed in a conical shape, once a
rubbed amber stick is held near to it [57]. Later, in the year 1745, Bose [58] described
the discovery of the aerosols, which are formed when a high electric potential is applied
to a fluid and only a few years later, the same observation was noted and publicized by
Nollet [59]. In the year 1882 Lord Rayleigh calculated theoretically how much charge
a liquid droplet could carry before the surface tension of the droplet is overcome [60].
The droplet size for which the surface charge is equal to the electromagnetic repulsion
is called the Rayleigh limit. Geoffrey Taylor researched in the sixties what the influence
of a electric current on a water stream is [61]. He found out, that when the current lies in
a certain range, the water flow is split in small droplets which result in a constant flow
of droplets. The cone, which is formed at the beginning of this flow is called a Taylor
cone as shown in Figure 6.
The primary droplets obtained from the Taylor cone are getting smaller and smaller
because the solvent evaporates. Once the charge in the droplet is so high, that the
electromagnetic repulsion is higher than the surface charge of the droplet, the droplets
explode in a so called Coulomb explosion.
The Taylor cone, which occur when electrospinning or -spraying, can be seen as
equilibrium between two different pressures. On one side there is the pressure, which
results from the cohesion force, which holds the liquid stream together. And on the
other side, there is the pressure, which comes from the electric field, which is induced
from the high power supply [63]. The two mentioned pressures are shown in Figure 7.
The surface tension tries to minimize the surface, this leads to a pressure, which can
be described with following equation:
~pγ = γκ (1)
17
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Figure 6: The liquid forms a Taylor cone when exiting the needle and so leading to primary
droplets. These evaporate as long as the surface tension is larger than the repulsion
of the charges. Once the repulsion is higher the droplets explodes in a Coulomb
explosion. Figure customized from Hawkridge [62].
Figure 7: Taylor cone, which occurs when electrospinning or -spraying with the most important
parameter. ϑ is the Taylor angle, ~pE the pressure from the electric field, ~pγ the pressure
from the cohesion force and r the distance between the needle to the point P [63].
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~pγ is the resulting pressure, γ the surface tension and κ the curvature of the surface.
The equation for the calculation of the electrostatic pressure ~pE is:
~pE = 0.50E
2 (2)
Here E is the electric field on the surface and 0 the vacuum permittivity, which is
8.85× 10−12 Fm−1.
For the Taylor cone to reach a stable condition both pressures has to be the same.
This is only the case for ϑ = 49.3°, for a detailed derivation of this angle the reader is
referred to the literature [63]. Thus the Taylor cone is 49.3°, from which with high flow
rates a jet is build up from the Taylor cone, which breaks up in droplets.
In these droplets the solvent evaporates further which leads in a diminishing of the
volume, but the charge is still the same. As already mentioned Lord Rayleigh showed
in his work, that the droplets are stable, as long as X is bigger than 1 in the following
equation [60,64]:
X =
Q2
64pi20γr03
(3)
Here r0 describes the radius of the droplet, γ the surface tension and Q the charge.
Once X is bigger than 1, the charge of the droplet, Q, is too large for the surface ten-
sion and the droplet explodes in a so called Coulomb fission in a spray, which is called a
Reyleigh jet. In the case of electrospinning or -spraying the jet is the desired result and
the produced fibers or beads, respectively, are collected.
The first patent, which was filled in for electrospinning was done in the year 1934 by
Anton Formhals [65]. From this moment on, it took still about 60 years until Reneker
and his group rediscovered electrospinning and thus started the great success of this
method [66].
In the year 2002 Fenn received the Nobel Prize for his work with electrospraying to
analyze large biomolecules [67].
2.2.2. Working setup for electrohydrodynamic atomization
The setup for electrospinning or -spraying is shown in Figure 8 and consists of three
main parts [54,55]. The first part consists of a syringe, a needle and a syringe pump to
control the flow of the polymer-solution. The second part is the high voltage power
source, which is either connected to the needle, the collector or both. And the last part
is the collector, which can either be grounded or also connected to the high voltage
power source.
The whole setup can also be expanded with a grounded or charged metal ring after
the needle to focus the spray. Also different kind of collector plates can be used, e.g. a
mesh or a rotating drum. Even if the setup seems easy and simple to use, there are a lot
of different parameter, which can be changed and even have to be in the right dimension
to work in the first place.
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Figure 8: Setup for electrospinning, consisting of a needle, a high voltage power source and a
collector [55].
The solvent of the polymer solution needs to have a low surface tension to be able
to evaporate fast enough for the process. It also must be conductive to take the charge
from the high voltage power supply and last but not least it must of course be able to dis-
solve the used polymer. With the right choice of the solvent it is also possible to choose
the resulting surface of the fibers or the beads. When using a solvent with low vapor
pressure and a high boiling temperature (e.g (N, N-dimethylformamide) (DMF)) the sol-
vents evaporates slower and results in a smoother surface, whereas when using solvents
with high vapor pressure and a low boiling point (e.g. Dichloromethane (DCM)) the
surface gets porous, because of the fact, that water condensates on the surface an builds
up a two-phase system, which then leads to the porous system when evaporating.
There are also different spraying modes, which can be chosen from, when adjusting
the flow rate and the applied voltage. Most of these modes can finally be grouped
together into two different categories: Dripping mode and jet mode [52]. The jet mode is
the desired one, because the spray is continuous and regular.
Finally the collector can also vary depending on the aimed results. When using a
stationary collector the fibers will be randomly distributed, but it is also possible to use
a rotating collector, which generates aligned fibers according to the rotational speed of
the collector [68]. If a non-conductive collector is used, the charge from the fibers can not
be dissipated to the collector and thus repel each other, which leads to a lower packing
density of the collected fibers.
The main difference between electrospinning and electrospraying comes from the
concentration of the polymer in the solution, as is shown in Figure 4 [50]. Some of the
parameter, flow rate, needle-collector distance, applied voltage and concentration of the
polymer were studied in a design of experiments (DOE) shown in chapter 4.1.2. Table
2 shows different parameter and the effect on the fiber morphology [68].
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Table 2: Effects of electrospinning parameter on fiber morphology [68]. The bold parameter were
studied in this work and the results are shown in chapter 4.1.2.
Parameter Effect on fiber morphology
Applied voltage ↑ Fiber diameter ↓ initially, then ↑
Flow rate↑ Fiber diameter ↑
Distance between capillary and collector ↑ Fiber diameter ↓
Polymer concentration (viscosity) ↑ Fiber diameter ↑
Solution conductivity ↑ Fiber diameter ↓
Solvent volatility ↑ Fibers exhibit microtexture
EHDA can be used for many applications. For example it can be coupled to a mass
spectrometer to analyze bigger bio-molecules like proteins, due to the multiple charge
on the molecules the m/z-ratio is smaller and so measurable. This method is called elec-
trospray ionization (ESI) and another advantage is that the ESI is a soft ionization, which
will not destroy the analyte and only form very few fragments. For this application Fenn
received, as already mentioned, the Nobel Prize in 2002.
Beside ESI there are many fields of application for EHDA. Nanofibers are used today
for photocatalytic self-cleaning car mirrors, a uniform coating material for car bodies,
building materials, stain-repellent, breathable clothes, bioengineering structures and tis-
sue engineering, optical devices, chemical sensors or filter materials [69–73]. The advan-
tage of EHDA is the uniform coating of the desired material, the inexpensive setup as
well as the possible to work in ambient conditions [74].
EHDA is also used widely in the food industry for coatings or bacterial-free pack-
aging or for releasing fertilizer in the agriculture [75]. When releasing fertilizer from
electrosprayed beads, the concentration can be better controlled and the loss to the at-
mosphere can be reduced.
For a wound to heal, the body and the immune system has to undergo five differ-
ent phases: wounding, hemostasis, inflammation, proliferation and remodeling [76,77].
Müller et al. [78] researched if incorporating Ca-polyphosphate and retinol into nano-
fibers have a positive effect on wound healing or more precisely on cell growth and
metabolism. They found out that if retinol was encapsulated into a Ca-polyphosphate
nanoparticle the cell growth was amplified.
It is even possible to create a small handhold device, which can be used directly on
the skin to create fibers for wound healing. The device can be loaded with different kind
of polymers and also of drugs and so can be used for different kind of wounds or skin
applications. The device is shown in Figure 9.
An overview over different methods and results from electrospray research is shown
in Table 3. All of the mentioned beads were done with a simple setup. The material
columns shows, that a wide range of polymers and also other chemicals are suitable
for electrospraying. Ethanol is an often used solvent, because it is easy to handle and
also with the low boiling point evaporates fast enough for the EHDA process. All the
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Figure 9: Handhold device for wound healing [55]. The device can be loaded with different
polymers and also drugs.
concentrations are in the lower percentage range, because, as was shown in Figure 4,
the difference between the electrospraying and electrospinning lies mostly in the con-
centration of the solution.
One way to incorporate another material in fibers is with a coaxial setup. For this, a
second solution is needed and one of them has to sheet the other, as shown in Figure
10a. Both solution, the core and the shell can also be seen in the Taylor cone, as can be
seen in Figure 10b.
(a) Experimental setup (b) Taylor cone
Figure 10: (a):Experimental setup to form fibers with a coaxial architecture [79].
(b): Taylor cone of a coaxial setup, the core solvent can clearly be seen [80].
One of the main difficulties in coaxial electrospinning is to find the right parameter
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to get coaxial fibers, which is challenging because of the fact, that one can change a
lot of parameter in the whole setup. Due to two different polymers and sometimes also
two different solvent most the parameter shown in Table 2 has to be considered for both
polymers. The parameter are also shown again in Figure 11 for a better overview [81].
Figure 11: Overview of the effects of electrospinning parameter on fiber/particles diameter [81].
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Table 3: An overview over different methods and results of research in the area of electrospraying. The used solutions and parameter were studied and
listed.
Year Material Solvent Flow rate Nozzle-∅ Current Distance Collector Counter- Particlesize
[µl min−1] [µm] [kV] [cm] Electrode [nm]
1994 [63] Rhodamine G (6.5mmol l−1) Acetone - - 2.8 1 a - -
2012 [82] Nickel(II) acetate (120mmol l−1) Butanol & MeOH 500 600 6.3 - c 2 10 to 20
2013 [83] SA, EC (50% (w/v)) EtOH 10 450 8 to 19 20 d with DDW - 62
2014 [84] PMSQ & PVA(10% (w/w)) EtOH 15 330 8 5 d with EtOH & water - 62
2015 [85] EC (2.5% to 10% (w/v)) EtOH 15 450 1 to 20 10 a - 10 to 90
2015 [86] NOSC (Tristearin) (0.1% (w/v)) DMSO, DCM 5 to 11 508 15 to 17.9 2.5 to 10 e - 180 to 270
2013 [87] PCL & PMSQ (5% to 12% (w/v)) EtOH, DCM, DMC 5, 50 and 300 200, 1000 and 2000 6.9 to 7.9 0.5 to 30 d with EtOH - 220 to 320
2009 [88] PLA (1% to 6% (w/v)) EtOH & DCM 2 to 10 50 2 to 8 3.5 b 2 200 to 800
2012 [89] Niflumic acid (20mgml−1) Acetone 30 to 35 150 to 1370 4.7 1.7 a - 200 to 800
2009 [19] Lipids EtOH 6 to 20 800 3 10 a with PBS 1 100 to 2500
2015 [90] PLGA (5% (w/v)) Acetone & MeOH 20 1770 9 to 13 7 a - 2100 to 3800
2013 [17] Acetyl. Dextran (50mgml−1) DCM 2 to 5 600 4.5 7 a - 1000 to 5000
EtOH: Ethanol, PLA: Polylactid acid, DCM: Dichloromethane, MeOH: Methanol, PCL: Polycaprolactone, PMSQ: Polymethylsilsesquioxane, DMC:
Dimethyl carbonate , SA: Stearic acid, EC: Ethyl cellulose, PVA: Polyvinylalcohol, PLGA: Poly(lactic-co-glycolic acid), NOSC: N-octyl-O-sulfate
chitosan, PEVA : Phosphate-buffered saline, DDW: Double deionized Water.
1 Grounded ring, 2 Charged ring.
a Grounded Plate, b Solventbeaker, c Reductive bath, d Petridish, e Heptane solution.
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2.2.3. Electrohydrodynamic atomization for drug delivery
EHDA can help to encapsulate a drug for better bioavailability, because nearly half of
the new API found today with the help of HTS have a low water solubility [3,4]. When
encapsulating in a polymer, the drug can be made easier available into the body and
with the wide range of possible polymers, one can adjust the desired release profile
to the drug, e.g. for a fast releasing the polymer PVA and for a slow releasing PCL,
respectively [91]. The polymer used for drug delivery has to be biocompatible and also
biodegradable, as to not have an operation for extracting the polymer once it is used,
and must have no effect on the human homeostasis. Also the polymer offers a better
drug stability when incorporated in a polymer than when spun monoaxial.
Another advantage of EHDA process is the possibility to create small particles in the
nanometer range, because particles smaller than 400 nm can not be detected through
the immune system in the human body and so can be transported in the blood vessels
without being extracted [52]. Also the possibility of tailoring the size of the particles
can help to adjust the release rate [92]. Small particles or fibers have a higher surface
to volume ratio and the drug is nearer to the surface than for bigger particles or fibers,
where the drug is more encapsulated in the core.
To achieve the best biocompatibility of the fibers with the cells in the human body
would be to create the fibers in such a way, that they mimic the extra cellular matrix
(ECM) in a good way, but for this the process of the deposition of the fibers has to be
better understood [93].
Table 4 show different results of the usage of EHDA for drug delivery.
Kenawy et al. [94] produced fibers from poly(lactic acid) (PLA) and poly(ethylene-
co-vinyl acetate) (PEVA) with tetracycline hydrochloride as the model drug to spin with
the polymer. The setup was done monoaxial and both polymers were spun either alone
or in a 50:50 mixture, all of them with a loading of 5 wt% of tetracycline hydrochloride,
but as no encapsulation efficiency was calculated the resulting loading can not be given.
The PLA spun mat released after less than one hour the maximal amount of the drug,
which was around 35%. The PEVA mat released the drug in a more or less linear profile,
achieving around 60% after 120 h. The mixture of both in comparison had also a linear
release profile but only released around 40% after 120 h.
The same research group researched years later the release of a drug, ketoprofen,
from PCL and poly(urethane) (PU) spun fibers [95]. The group also made, as before,
a mixture of both polymers in 25/75, 50/50, 75/25 blends. The release studies were
done for 360 h and PCL and PU released after this time around 70% to nearly 100% of
the calculated ketoprofen amount from the fiber mats. The blend released 60% to 90%
after the measured 360 h. In this study no big differences between the polymers among
themselves and between the polymers and the blends could be found. All fiber mats had
a drug loading of around 5 wt%.
Another work done with ketoprofen was the encapsulation of it in different concen-
trations of ethyl cellulose (EC) [96]. The chosen ratios between the drug and the polymer
were 1:1, 1:2, 1:4 and 1:10, and the resulting beads were then examined in a release
study. The drug loading for the beads ranged from 9% to 50% of the weight of a bead.
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Table 4: An overview over different methods and results of research in the area of electrospinning. The focus was also directed on the encapsulation of
Ibuprofen, as was done in this thesis.
Year Drug Loading Core Material Shell Material Preparation Method Fiber-∅ [nm] max. Release Rate
2002 [94] Tetracycline HCl 5 wt% - PEVA, PLA Monoaxial 1000 to 3000 60%
2009 [95] Ketoprofen 5 wt% - PCL Monoaxial 2000 to 7000 90%
- PU Monoaxial 3000 to 6000 50%
2012 [96] Ketoprofen 9 wt% to 50 wt% - EC Monoaxial 8.4 to 11.6 100%
2014 [97] TA 1:5 & 1:10 - PLGA Monoaxial (Spraying) 50 to 100 40%
- PLGA Monoaxial (Spinning) 500 to 1500
2016 [98] Prednisolone 7 wt% to 38 wt% - EDS Monoaxial 450 to 650 -
2010 [99] Metoclopramide HCl 1 wt% PVA PCL, PLGA, PLLA Coaxial - 75%
2010 [100] Paclitaxel, Suramin ≈1 wt% for both PLLA PLGA Coaxial - 100%
2014 [101] Amoxicillin 4 wt% PGA CA, Gelatin Coaxial 134 100%
2014 [91] Quercetin 1 wt% EC PVP Coaxial 830 to 860 97%
2015 [102] ASA 1:10 PCL PCL Coaxial 1800 to 3400 100%
2013 [103] Ibuprofen 2 wt% - Zein Monoaxial 1780± 310 100%
2015 [104] Ibuprofen 5 wt% - PCL Monoaxial 1237 20%
- pNIPAM-co-MAA Monoaxial 1608 65%
2013 [105] Ibuprofen 1 wt% to 10 wt% - PLGA Monoaxial 2000 to 5000 0.33 µmolml−1
2013 [106] Ibuprofen 3 wt% DMF Zein Coaxial 940± 340 100%
2013 [107] Ibuprofen 10 wt% DMAc PAN, PVP Coaxial ≈ 500 97.8%
PEVA: Poly(ethylene-co-vinyl acetate), PLA: Poly(lactid acid), HCl: Hydrochloride, PCL: Poly(-caprolactone), PU: Poly(urethane), PLGA: Poly(lactic-co-
glycolic acid), PLLA: Poly(L-lactide acid), EC: Ethyl cellulose, PGA: Poly(vinyl alcohol), CA: Cellulose Acetate, PVP: Poly(vinyl pyrrolidone), TA: Triamci-
nolone acetonide, ASA: Acetylsalicylic acid, EDS: Eudragit S100, DMAc: N,N-dimethylacetamide
26
2. THEORETICAL BACKGROUND Master-Thesis, FS 2017
As can be expected, the beads with the highest drug-polymer ratio (1:1) were released
the fastest and also the most, with nearly 100% after 24 h and on the other hand, the
particles with the lowest ratio, only released around 60% of the drug at the end of the
study. The work showed, that it is possible to control the release rate and also the amount
released with the ratio between the drug and the polymer.
Jahangiri et al. [97] used a monoaxial setup to make PLGA-beads and -fibers with
triamcinolone acetonide as drug. The drug:polymer ratio in the solution were 1:5 and
1:10, but again as before, the resulting drug loading in the beads or the fibers was not
calculated. Release studies showed that after 8 h only between 25% to 40% of the drug
was released. The lower percentage was achieved by the fibers with a ratio of 1:10 and
the higher percentage with ratio 1:5.
Huanbutta et al. [98] encapsulated prednisolone in Eudragit S100, a polymer mixture
made from Evonik for targeted and time-dependent drug delivery. The loading of the
drug ranged from 7 wt% to 38 wt% and the resulting fibers were tested for their physical
properties and stability. No release studies were done in this work.
Tiwari et al. [99] showed the possibility to spin a drug coaxial in a polymer shell.
For this they used PVA as core polymer and three different polymers as shell polymer:
poly(L-lactide acid) (PLLA), PCL and poly(lactic-co-glycolic acid) (PLGA). With all
the core-shell fiber mats release studies of 360 h were studied and the PVA-PLGA core
shell fiber mats showed the best result. For this setup around 75% of the drug, Meto-
cloparmide HCl, were released, whereas for the PVA-PCL and the PVA-PLLA fiber
mats the total released amount was 65% and 25%, respectively. The core had a drug
loading of 1 wt% but the encapsulation efficiency was not calculated, so it is not possi-
ble to know how much of the drug was encapsulated in the fibers at the end.
A new approach was tried from Nie et al. [100], where they tried to encapsulate two
different drugs, a hydrophobic, paclitaxel, and a hydrophilic, suramin. Both variations
of encapsulation, hydrophilic in the shell and hydrophobic in the core (A) and vice versa
(B), were studied and analyzed with the help of release studies. It could be shown, that
both variations are possible to create and that with the choice of the drug in the core and
the one in the shell the release can be controlled. The drug loading of A was around
1.7 wt% for paclitaxel and 0.8 wt% for sumarin and for B 1.1 wt% paclitaxel and 1.8
wt% suramin. For variation A only around 60% of the hydrophobic drug in the core
is released after 30 d and nearly 100% of the hydrophilic drug in the shell, however
with variation B, nearly 100% of the hydrophilic drug from the core is released and
around 85% of the hydrophobic drug from the shell. The multidrug approach can also
be used for example with a fast anti-inflammatory drug and a slower tissue recovery
drug afterward [108].
Kiatyongchai et al. [101] used the coaxial setup to encapsulate amoxicillin with PEG
as core polymer in a cellulose acetate (CA) and gelatin blend. The release of the drug
from the coaxial fibers was studied over a time span of 24 h and 100% of the drug was
released after this time. The loaded amount of the drug was around 4 wt% of the fibers.
Coaxial made fibers from PVP as the shell polymer and EC as the core polymer were
made by Li et al. [91] to encapsulate quercetin. Unlike other works, quercetin was
mixed in both solution, core and shell, with 1 wt% in the core and 1 wt% to 3 wt% in
the shell. The final drug loading of the fibers with quercetin was not calculated. After
24 h between 85% and 97% of the quercetin was released from the fibers during the
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release studies.
A release study a lot longer than any other work was done by Repanas and Wolkers
[102], when they let acetylsalicylic acid be released from PCL-fibers over a time frame
of three month, where nearly 100% was released, after the first 8 h only around 60% for
conventionally made fibers and around 30% for coaxial made fibers. The total amount
of the drug was not calculated but the initial ratio in the core solution between drug and
polymer was 1:10.
Ibuprofen, the model drug used in this thesis was a model drug for some research
work done in the past in the context of encapsulating APIs. Li et al. [103] and Huang
et al. [106] both used a system of zein/Ibuprofen to encapsulate Ibuprofen. The first
was done monoaxial with a 12% zein and 2 % Ibuprofen ethanol solution. The resulting
nanoparticles had a diameter of 1.78 µm± 0.31 µm and they released 100% of the en-
capsulated Ibuprofen after 36 h. The latter work tried to spin the system with a coaxial
setup, using a solution of 30% zein and 3% Ibuprofen in ethanol as core and pure DMF
as shell. The resulting fibers had a diameter of 0.94 µm± 0.34 µm for a flow rate ratio
of 1:9 between the shell and the core. The fibers released all of the Ibuprofen after 2 h
with a burst release of 40% to 45% after the first hour.
The temperature and pH sensitive polymer pNIPAM, which was already mentioned
in previous chapters, was used to test the hypothesis of a temperature or pH sensitive
release profile [104]. Ibuprofen was used as released drug and for comparison the same
experiments were done with a PCL mat. Both microfibers contained 5 wt% Ibuprofen
and the release of Ibuprofen from PCL was as expected neither temperature nor pH sen-
sitive and only around 10% to 20% of Ibuprofen was released after 4 h. In comparison
to PCL pNIPAM showed a significant relationship between the temperature and the pH
and the releasing of Ibuprofen. With pH 7.4 only 40% of the encapsulated Ibuprofen
was released and with pH 1.7 it was 65% after 4 h, both experiments done at room tem-
perature. The temperature dependency was shown with both experiments done at 40 ◦C,
where only 5% to 10% were released after the measured 4 h.
Cantón et al. [105] used the biodegradable polymer PLGA to encapsulate Ibuprofen
in a monoaxial setup. For this two different solution were prepared, one with 20%
PLGA and the other with 25% PLGA. To those solution different concentrations of
Ibuprofen were added, from 1% to 10%. The fiber diameter ranged from 2 µm to 5 µm
and the release of Ibuprofen from the fibers was after 7 d 0.33 µmolml−1. The fibers
produced with this setup could be used in scaffold used for tissue regeneration, as they
would release small amount of Ibuprofen over a long time and could so help to decrease
the pain.
Another drug-loaded coaxial prepared nanocomposite was produced by using a core
of 15 g of PAN and 2 g of Ibuprofen in 100ml of N, N-dimethylacetamide (DMAc)
and a shell of pure DMAc [107]. The flow rate had a shell:core ratio of 1:9. Different
concentrations of PVP into the core were tried out, from 0% to 22.7% and the resulting
fibers had a diameter of 0.44 µm± 0.14 µm to 0.65 µm± 0.12 µm. The fibers showed a
burst release of 36% in the first hour in the release studies and after 36 h from 73.4% to
97.8% of the loaded Ibuprofen was released. The lower value was for the fibers without
PVP and the higher values for those with the highest PVP amount in them.
But not only EHDA research was done to encapsulate Ibuprofen, as can be seen
with the following four researches [109–112]. The first used lipid nanocarriers to transport
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Ibuprofen in pain treatments. As lipid phase a mixture out of two different commer-
cially available lipids (Solutol® HS15 from BASF AG and Lipoïd® S75-3 from Lipoïd
GmbH) were used. Three different solution were prepared, 1:50, 1:10 and 1:5 for the
Ibuprofen:lipid ratio. The so produced lipid nanocapsules had a size of around 55 nm
and a encapsulation efficiency of 95%. The release study was conducted over a time
span of 24 h and at the end of the study all of the encapsulated Ibuprofen was released.
Plakkot et al. [110] produced nanoparticles made out of either 2% or 15% Ibuprofen
and 0.5% PVP, 0.5% Hydroxypropyl methylcellulose (HPMC) and 0.1% Sodium lauryl
sulphate (SLS). The avarage size of the produced nanoparticles were <300 nm. The
particles released 90% of the encapsulated Ibuprofen already after 60min.
An encapsulation of Ibuprofen into spray-dried silica microsphere was done by Fat-
nassi et al. [111]. The loading of the Ibuprofen was 16% and the produced microsphere
had a diameter of 4 µm. With the help of NMR they could prove that the Ibuprofen
is found in nano-domains of 20 nm to 100 nm and not elsewhere in the microspheres.
They released around 50% of the encapsulated Ibuprofen after 120min.
The last work was done by Nada et al. [112], where they used ultra-homogenization
to make nanoparticles and nanosuspensions with Ibuprofen. PVP was used as polymer
to encapsulate the Ibuprofen and drug concentrations ranging from 0.5% up to 10%
were tried out. The average particle size of the nanoparticles was 527 nm± 31 nm and
the encapsulation efficiency for all experiments was 97.5% to 102%. The release rate
of the particles was studied for 60min and 90% to 100% of the Ibuprofen was released
during that time.
Even if there is a lot of research done and literature reporting on drug delivery through
EHDA, there is still no commercially available product around [113]. One disadvantage
of the setup is the low throughput and also the difficult up-scaling, due to the fact, that
higher flow rates or bigger nozzles are not possible. Multiplex setups, a setup with
different nozzles, are a possible way of up-scaling but the uniform distribution of the
electric field has to be proven possible for this to work. Also most of the studies done
today are in vitro and not in vivo [114]. As can be seen in the descriptions of the works
above, the drug loading efficiency and content are also still quite low and must be im-
proved. Furthermore the effect of the polymer on the human body has to be researched,
as whether some side effects has to be considered. For further details on nanofibers and
drug delivery the interested reader is referred to the reviews of Greiner and Wendorff
[55] and Sill and von Recum [68].
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3. Materials and methods
3.1. Materials
PCL with a Mw of 80 000 Da, PVP with either a Mw of 55 000 Da or 1 300 000 Da were
purchased from Sigma Aldrich and PVA was used as a commercially available 16 wt%
solution in water called Sloviol 2, all chemical properties of the polymers are shown in
Table 5. As solvents ethanol (≈99%) was purchased from Sigma Aldrich, Chloroform
(CHCl3, 99%) from Acros Organics and acetic acid (99.7%) from abcr.
Table 5: Used polymer sand their chemical properties.
Data PVP PCL PVA
Chem. Formula [C6H9NO]n [C6H10O2]n [C2H4O]n
CAS-Nr. 9003-39-8 24980-41-4 9002-89-5
Mol. Weight (mol g−1) 111.14 · n 114.14 · n 44,05 · n
GHS-Symbol - - -
Supplier Sigma Aldrich Sigma Aldrich Elmarco
3.2. EHDA methods
During the thesis different EHDA experiments were done, as well monoaxial as coaxial
experiments. All experiments used the same setup: a high voltage power source, one or
two syringe pumps, a nozzle and a collector.
Two different high voltage power sources were used, the first one (Fug HCN 35-
35000, Schechen DE) was connected to the nozzle and through this the main voltage
was applied and the other power source (iseg T1 CP300p, Radeberg DE) was connected
to the collector to build up a counter electrode. The working range of the high voltage
power source for all experiments was between −15 kV to −25 kV between nozzle and
collector.
3.2.1. EHDA setup
For the coaxial experiments two syringe pumps were used (New Era NE-300, Farm-
ingdale NY, USA and Harvard Apparatus PHD Ultra, Holliston MA, USA) to have the
possibility of two different flow rates for the shell and the core. The diameter of the
nozzle was for every experiment the same. The used nozzle-setup for the coaxial spun
fibers is shown in Figure 12. The shell and the core solution could be transferred with
two different entry points to the nozzle.
An aluminum foil span around a copper plate with a distance from nozzle to collector
of 10 cm to 20 cm was used to collect the fibers or particles if not other stated.
As already mentioned before, three different polymers, PCL, PVP and PVA, were
used for monoaxial and coaxial experiments.
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Figure 12: a.) Components of the nozzle-setup for coaxial spun fibers. The nozzle could be
interchanged with similar nozzles of different diameter, which was not done in this
thesis. b.) Built nozzle-setup with connector for shell and core solution. c.) View
from bottom with the exit of the nozzle, the nozzle is in the center of the exit and the
shell solution would be around the core solution.
3.2.2. Design of experiments
To see the effects on the different parameter, which can be controlled during a EHDA
experiment, a DOE was done with PVP as polymer. The studied parameter were the
concentration of the polymer (0.4 gml−1, 0.5 gml−1 and 0.6 gml−1), the applied volt-
age (−15 kV,−20 kV and−25 kV), the distance from the nozzle to the collector (10 cm,
15 cm and 20 cm) and the flow rate of the polymer solution (0.5ml h−1, 1ml h−1 and
1.5ml h−1) [115]. With this four parameter 27 different experiments were done and as the
result the amount of fibers collected on the collector in a defined time frame, which was
25min per experiment, the mean diameter and the relative standard deviation of the di-
ameter was calculated and furthermore the correlation between the four input parameter
and the output values was defined. Table 6 shows the 27 different experiments with the
chosen parameter.
The last three experiments have the same parameter as to solidify the center of the
DOE sphere. The DOE was done with a monoaxial setup, because with a coaxial setup
and therefore six parameter one would have to conduct 54 experiments, and when choos-
ing to see the effect of all parameter, that is also the nozzle diameter, the molecular
weight of the polymer and the solvent of the polymer, this would lead to nine different
parameter and 130 experiments.
3.2.3. Electrospraying vs. electrospinning
Also the effect on the concentration of PCL, PVP and EC were studied in the light of
the distinction between creating beads and fibers, as shown in Figure 4. For this four
different PCL solutions (0.1 gml−1, 0.15 gml−1, 0.2 gml−1 and 0.25 gml−1) in acetic
acid, four different PVP solutions (0.34 gml−1, 0.4 gml−1, 0.5 gml−1 and 0.6 gml−1)
in ethanol and four different EC solutions (0.042 gml−1, 0.064 gml−1, 0.088 gml−1 and
0.14 gml−1) in ethanol were prepared and all spun with an applied voltage of −20 kV,
a flow rate of 1ml h−1 and a distance of 15 cm from the nozzle to the collector [79].
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Table 6: Overview of the DOE experiments done with pure PVP for the determination of the
correlation of the four input parameter (concentration, voltage, distance, flow rate) and
the amount of fibers, the diameter of the fibers and the relative standard deviation.
No Concentration (gml−1) Voltage (kV) Distance (cm) Flow rate (ml h−1)
1 0.4 15 15 1
2 0.4 25 15 1
3 0.6 15 15 1
4 0.6 25 15 1
5 0.5 20 10 0.5
6 0.5 20 10 1.5
7 0.5 20 20 0.5
8 0.5 20 20 1.5
9 0.4 20 15 0.5
10 0.4 20 15 1.5
11 0.6 20 15 0.5
12 0.6 20 15 1.5
13 0.5 15 10 1
14 0.5 15 20 1
15 0.5 25 10 1
16 0.5 25 20 1
17 0.4 20 10 1
18 0.4 20 20 1
19 0.6 20 10 1
20 0.6 20 20 1
21 0.5 15 15 0.5
22 0.5 15 15 1.5
23 0.5 25 15 0.5
24 0.5 25 15 1.5
25 0.5 20 15 1
26 0.5 20 15 1
27 0.5 20 15 1
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3.2.4. Drug encapsulation with EHDA
Finally different possibilities to form coaxial fibers with Ibuprofen were studied. Mono-
axial experiments with PVP and Ibuprofen, as they are both soluble in EtOH, as well as
coaxial experiments with PCL, PVP and PVA with Ibuprofen were studied. As solvents
EtOH was used for PVP, water for PVA and CHCl3 and acetic acid for PCL. The release
from Ibuprofen out of the different polymers fibers were studied as well as the release
from different concentrations of PCL as shell polymer. The efficiency of encapsulation
and the effective release of the drug from the fibers were calculated using the initial flow
rate.
3.3. Fiber characterization methods and in vitro drug release
For the analysis of the fibers different methods and instruments were used to character-
ize as many parameter as possible.
3.3.1. Characterization techniques
For the characterization of the diameter and the morphology of the fibers and the beads
scanning electron microscopy (SEM) (Fei Quanta FEG 250, Hillsboro OR, USA) was
used. The applied voltage in the pressure chamber was 5 kV and the pressure was
40mbar and all the samples were sputtered beforehand with a conductive layer on the
sputtering machine (Quroum Q150R S, East Sussex, GB). For the investigation of the
composition of the fibers and beads Fourier transform infrared spectroscopy (FTIR)
(Bruker Tensor 37, Billerica MA, USA) with a golden gate setup and ATR mode was
used. For a further understanding of the coaxial experiments Raman spectroscopy was
used to study the architecture of the core-shell nanofibers and -particles.
3.3.2. In vitro drug release
The release studies were done in a dissolution testing device (AT7 Smart Sotax, Aesch,
CH). The fiber mats were put in 900ml of phosphate-buffered saline (PBS) with a pH
of 7.2 and at a temperature of 37 ◦C and after predefined time steps 5ml were taken and
replaced with new PBS to maintain a constant volume.
The amount of Ibuprofen released at each time step was either measured with ultra-
violet visible spectrophotometry (UV-VIS) (Analytik Jena Specord S600, Jena, DE) at
a wavelength of 220 nm or with high performance liquid chromatography (HPLC) (Ag-
ilent Serie 1200, Santa Clara CA, USA). The used column was a C18 column and as
mobile phase A H2O / 0.1% formic acid and B acetonitrile / 0.1% formic acid were used.
The used gradient is shown in Table 7. The measured time was 10min and the post time
3min with a flow rate of 1mlmin−1 and the detection was made at a wavelength of
254 nm.
The calibration curve for the HPLC in the range of 5 µgml−1 to 600 µgml−1 is plotted
in Figure 13. The fit for the calibration has the function y(x) = 0.0145 · x.
For the characterization of the release different time dependent properties were cal-
culated [97], t25% and t50% are the time at which 25% and 50% of the drug is released and
Q5min, Q1 h, Q50% and Q100% the amount of drug released after 5min, 1 h, after 50%
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Table 7: Used gradient for the HPLC method.
time (min) % B
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Figure 13: HPLC calibration curve for Ibuprofen in the range of 5 µgml−1 to 600 µgml−1 with
the function y(x) = 0.0145 · x.
and at the end of the measured time of the release study. The different properties are
shown in Figure 14 with the result of a release study done with a coaxial fiber mat with
0.1 gml−1 PCL in chloroform and 0.25 gml−1 Ibuprofen in ethanol.
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Figure 14: Calculated properties of the release studies. The values are used to compare different
release studies according to their velocity of releasing the drug.
The results of the release studies were also compared to the therapeutic window of
Ibuprofen, which lies between 150 µmol l−1 and 300 µmol l−1 [5].
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Table 8: Overview over all experiments in chapter 4. The experiments done in chapter 4.1 are optimization experiments and with the bold marked
experiments done in chapter 4.2 release studies were done and the results are shown in chapter 4.3.
Shell Core
Component Concentration (gml−1) Solvent Flow rate (ml h−1) Component Concentration (gml−1) Solvent Flow rate (ml h−1) Voltage (kV) Distance (cm) Chapter
Ethyl cellulose 0.042, 0.064, 0.088 and 0.14 EtOH 1 - - - - −20 15 4.1.1
PVP 0.34, 0.4, 0.5 and 0.6 EtOH 1 - - - - −20 15 4.1.2
PCL 0.1, 0.15, 0.2 and 0.25 Acetic acid 1 - - - - −20 15 4.1.3
PCL 0.15 ac. acid, EtOH, TFE 1 - - - - −20 15 4.1.3
PCL 0.15 TFE 1 PVP 0.1 TFE - −20 15 4.1.3
PCL 0.15 benzene 1 PVP 0.5 EtOH 0.5 −20 15 4.1.3
PCL 0.15 Acetic acid 1.65 Meth. blue - EtOH 0.75 −20 15 4.1.3
Ethyl cellulose 0.064 EtOH 0.8 - - - - −25 15 4.2.1
Ethyl cellulose 0.064 EtOH 0.45 Ibu 0.2 EtOH 0.05 −25 15 4.2.1
Ethyl cellulose 0.14 EtOH 0.45 Ibu 0.1 EtOH 0.05 −25 15 4.2.1
PVP 0.34 EtOH 0.5 Ibu, EC 0.15 and 0.15 EtOH 0.3 −25 15 4.2.2
PVP 0.34 EtOH 0.7 Ibu, EC 0.15 and 0.15 EtOH 0.4 −25 15 4.2.2
PVP 0.31 EtOH 0.8 Ibu 0.1 EtOH 0.7 −25 15 4.2.2
PVP 0.31 EtOH 0.8 Ibu 0.2 EtOH 0.7 −25 15 4.2.2
PVP 0.5 EtOH 1.2 Ibu 0.2 EtOH 0.5 −20 15 4.2.2
PVP 0.5 EtOH 0.7 Ibu 0.2 EtOH 0.4 −20 15 4.2.2
PVA 16 wt% Water 0.45 Ibu 0.25 EtOH 0.5 20 15 4.2.3
PCL 0.15 Acetic acid 1.65 Ibu 0.2 EtOH 0.75 −20 15 4.2.4
PCL 0.2 Acetic acid 1.65 Ibu 0.2 EtOH 0.75 −20 15 4.2.4
PCL 0.1, 0.15, 0.2 and 0.25 Chloroform 1.65 Ibu 0.25 EtOH 0.75 −20 15 4.2.4
PCL 0.1, 0.15, 0.2 and 0.25 Chloroform 1.65 Ibu, PVP 0.25 and 0.5 EtOH 0.75 −20 15 4.2.4
EtOH: Ethanol, TFE: 2,2,2-trifluorethanol, Ibu: Ibuprofen, EC: Ethyl cellulose, Meth. blue: Methylene blue
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4. Results and discussion
The aim of this thesis was, as already mentioned in chapter 1.3, to encapsulate Ibuprofen
in different polymers in a core-shell architecture and to conduct release studies with
these fibers to investigate the release rates and the encapsulation efficiency. An overview
over all experiments done in the following chapters is given in Table 8. The results of
the experiments are shown in the next chapters and the release studies of the coaxial
prepared fibers with Ibuprofen are shown in chapter 4.3 with an overview over all the
release studies listed in Table 9.
4.1. Optimization of electrospinning or electrospraying
conditions
For every polymer before the coaxial electrospinning with Ibuprofen was conducted,
some pretrials were done to find the most suitable concentrations, solvents and also
flow rates to create a stable Taylor cone when spinning.
4.1.1. Optimization of electrospinning or electrospraying conditions of
pure ethyl cellulose
The first experiments were done with ethyl cellulose (EC), because some promising
literature was found on encapsulations done with EC [83,85]. For this, four different
solutions with different concentrations (0.04 gml−1, 0.064 gml−1, 0.088 gml−1 and
0.14 gml−1) of EC in ethanol were prepared and spun. The flow rate was always
1ml h−1 and the voltage −15 kV.
As is depicted in Figure 15 the change from electrospraying to electrospinning is con-
centration dependent, as already mentioned in chapter 2.2.1 and shown in Figure 4 [50].
The magnification in all the images is the same and one can see, that the beads get bigger
from the 0.042 gml−1 solution to the 0.088 gml−1 solution and also, that with a con-
centration of 0.064 gml−1 already small fibers starts to build, which are more dominant
in the 0.088 gml−1 solution and take completely over with the highest concentration.
The beads show a collapsed morphology, which comes from the fact, that the solvent
evaporates fast and the polymer is migrated with the solvent towards the outside of
the particles, leaving the center of it with a lower density and so they collapse onto
themselves [113].
4.1.2. Optimization of electrospinning conditions of pure PVP and design
of experiments
PVP solutions were always prepared in ethanol as solvent and for the first experiments
four different concentrations were tried out. For this concentrations of 0.34 gml−1,
0.4 gml−1, 0.5 gml−1 and 0.6 gml−1 of PVP (Mw =55 000Da) were prepared in ethanol.
As flow rate 1ml h−1 was chosen, the applied voltage was−20 kV and the distance from
the nozzle to the collector was 15 cm. The resulting mean diameters of the fibers ver-
sus the concentration of the solutions are plotted in Figure 16. A linear concentration
dependency on the mean diameter can clearly be seen.
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Figure 15: SEM images of particles/fibers obtained after spraying/spinning four different
EC concentrations (0.042 gml−1, 0.064 gml−1, 0.088 gml−1 and 0.14 gml−1) in
ethanol. The transition from spraying to spinning can be seen from the lowest con-
centration, only beads, over to 0.064 gml−1 and 0.088 gml−1, beads with fibers, to
the highest concentrations, where only fibers can be seen.
To see the correlation between the other input parameter of the EHDA setup on the
amount of fibers and the diameter of the fibers a design of experiments was conducted,
as described in chapter 3.2.2. The resulting correlation matrix of the four parameter
(rows) with the four output variables (column) is plotted in Figure 17.
For the first column, which is the amount of fibers found on the alumina foil after
25min, the evaluation was done by eye and the amount of fibers was rated between 1
(few fibers) and 5 (many fibers). The second column is the mean diameter which was
evaluated using Matlab and a function to calculate the diameter of the fibers. The third
column was also calculated using the same function and the fourth column was the rela-
tive standard deviation of the fibers. Figure 18 shows the three different concentrations
(rows) versus the three different distances (column) and the effect on the fiber diameter.
In the correlation matrix negative values (blue) means a negative correlation, so for
bigger concentrations the amount of fibers decreases, and a positive number (red) means
a positive correlation, so for bigger concentrations the mean diameter increases. When
comparing the correlation matrix to Table 2 one can see, that the founding of the DOE
corresponds to the effect of the literature [68]. Moreover the matrix also shows the mag-
nitude of the influence of each effect, for instance the effect of the concentration of the
polymer has the highest correlation with the mean diameter and also with the amount of
fibers found. With this one can tailor the fibers according to the desired function of the
produced fibers.
38
4. RESULTS AND DISCUSSION Master-Thesis, FS 2017
Figure 16: Mean diameters of monoaxial PVP fibers versus the concentration of pure PVP so-
lutions ranging from 0.34 gml−1 to 0.6 gml−1 in ethanol.
Figure 17: Correlation matrix of the DOE. The first column shows the effect on the amount
of fibers, the second is the mean diameter, the third is the standard deviation and
the fourth is the relative standard deviation. Red and blue indicate a strong positive
correlation and a strong negative one, respectively.
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Figure 18: The grid shows the influence of the polymer concentration and distance between
nozzle and detector on the diameter when electrospinning pure PVP from ethanol
according to the design of experiments.
4.1.3. Optimization of electrospinning conditions of pure PCL
Before using PCL to encapsulate Ibuprofen, some monoaxial experiments were done to
determine the best flow rate and also the most suitable concentration to spin coaxial.
For this, like for PVP, four different concentrations were prepared and then spun with
the same parameter. The used concentrations were 0.1 gml−1, 0.15 gml−1, 0.2 gml−1
and 0.25 gml−1 all in acetic acid. The flow rate was 1ml h−1, the applied voltage was
−20 kV and the distance always 15 cm.
The diameter has a dependency on the concentration of the polymer solution, only
the solution of 0.2 gml−1 do not follow the rule. This can have different reasons, as
one can see the difference between the 0.15 gml−1 solution and the 0.2 gml−1 is also
that with 0.2 gml−1the fibers stick more together and are connected together meanwhile
with 0.15 gml−1 the fibers are nicely separated. Also all experiments were only done
once, so the problem could also be a problem with the one experiment in the setup. For
most experiments the 0.15 gml−1 polymer solution was used, because the fibers had the
best properties.
In the next step, different solvents where tried out to spin PCL. Acetic acid, chlo-
roform and 2,2,2-trifluorethanol (TFE) were used as solvent to see, if they have an
influence on the fibers of PCL. The concentration used for all three experiments were
0.15 gml−1 of PCL and the flow rate was always 1ml h−1 and also the applied voltage
and the distance were the same as always. The resulting three SEM images can be found
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Figure 19: Mean diameters of monoaxial electrospun PCL fibers versus the concentration of
pure PCL solutions in acetic acid ranging from 0.1 gml−1 to 0.25 gml−1.
in Figure 20.
Figure 20: Influence on the solvent on the monoaxial electrospun PCL fibers. a.) Acetic acid,
b.) Chloroform and c.) 2,2,2-trifluorethanol as solvent. The concentration of PCL
was always 0.15 gml−1.
When using acetic acid the fibers tends to stick together, and also the differences
between the thinnest fibers and the thickest one is big, which is not desired, because this
would lead to differences in releasing the drug once a coaxial experiment will be done
with PCL.
TFE seems to be a good solvent for spinning PCL and it would also dissolve PVP,
which could be used in a blend experiment with PVP as core polymer. The blend done
with TFE and also one done with C6H6 as shell solvent can be seen in Figure 21 [116].
C6H6 as solvent was quickly dismissed because no fibers and also no beads could be
observed in the blend, as shown in Figure 21b.
Whereas TFE showed a fiber mat with a mean diameter of 1.74 µm± 0.21 µm, which
could be used for coaxial electrospinning with Ibuprofen. But when trying to do so,
Ibuprofen showed poor solubility in TFE. Only when heated during the ultrasound bath
the Ibuprofen was solved completely in TFE but afterward when cooled down to room
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(a) Shell: 0.15 gml−1 PCL in TFE
Core: 0.1 gml−1 PVP in TFE
(b) Shell: 0.15 gml−1 PCL in C6H6
Core: 0.5 gml−1 PVP in ethanol
Figure 21: Influence of the solvent on electrospun caoxial PCL-PVP fibers.
a.) The shell is a 0.15 gml−1 PCL solution in TFE and the core is a 0.1 gml−1 PVP
(Mw =1300 000 Da) solution in TFE. The obtained fibers show a smooth surface
and a uniform diameter
b.) The shell is a 0.15 gml−1 PCL solution in C6H6 and the core is a 0.5 gml−1 PVP
(Mw =55 000 Da) solution in ethanol. No fibers could be observed on the collector.
temperature crystals of Ibuprofen formed in the solution. This led either to the dismissal
of TFE as solvent or to a complicated setup to keep the TFE solution always above room
temperature.
For this reason, TFE was dismissed and chloroform was used as desired solvent for
PCL to encapsulate Ibuprofen and also to encapsulate a PVP-Ibuprofen mixture.
The next part of the pretrials was to find the best flow rates for both the shell and the
core. For this a 0.2 gml−1 solution of PCL in acetic acid as shell solution and for the
core a solution of methylene blue solved in ethanol was used. With the help of a CCD
camera (Compact USB 2.0 CMOS Cameras, Thor Labs, Newton NJ, USA) the flow
rates were adjusted until a stable cone jet could be observed. This was achieved with
a shell flow rate of 1.65ml h−1 and a core flow rate of 0.75ml h−1. With the so found
flow rates one could get the Taylor cone as shown in Figure 22.
The best setup was a 0.15 gml−1 PCL solution in chloroform as shell and the core was
a mixture of 0.5 gml−1 PVP (Mw =55 000 Da) and 0.25 gml−1 Ibuprofen in ethanol and
the flow rates were for the shell 1.65ml h−1 and for the core 0.75ml h−1. The distance
and applied voltage were 15 cm and −20 kV, respectively.
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Figure 22: Taylor cone of a coaxial experiment done with a 0.15 gml−1 PCL solution in chlo-
roform and a core of 0.5 gml−1 PVP and 0.25 gml−1 Ibuprofen in ethanol.
4.2. Coaxial experiments for encapsulating Ibuprofen
4.2.1. Coaxial experiments with ethyl cellulose and Ibuprofen
When trying to spin ethyl cellulose with Ibuprofen in a coaxial setup the results were
not as expected. Instead of getting beads, crystals were formed on the alumina foil and
so no beads or fibers could be observed. Figure 23 shows the effect on adding Ibuprofen
to the EC.
The concentration of ethyl cellulose was 0.064 gml−1 in ethanol and the flow rate
during the monoaxial experiment was 0.8ml h−1 with a voltage of −25 kV and 15 cm
between the nozzle and the collector. For the coaxial setup the concentration of the shell,
the ethyl cellulose, was the same and the concentration of Ibuprofen was 0.2 gml−1 in
ethanol. The flow rate of the shell was 0.45ml h−1 and for the core 0.05ml h−1, the
voltage and the distance were the same as for the monoaxial experiment.
When changing the concentrations of both solutions to 0.14 gml−1 of ethyl cellulose
in ethanol and 0.1 gml−1 of Ibuprofen in ethanol, fibers can be collected, but the fibers
stick together as they were glued, shown in Figure 24b. When using a concentration of
0.088 gml−1 for the ethyl cellulose crystals are formed, which have grown over night on
the alumina foil and the grain boundaries can be seen under the SEM, the crystals and
the grain boundaries are displayed in Figure 24a. All other parameter for the coaxial
setup were the same as mentioned above.
In these pretrials also two different setups were tested and their application was in-
vestigated. The first setup was with a charged copper ring between the nozzle and the
collector. The difficulty of the setup with the ring was that the ring would bring again
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(a) Monoaxial EC (b) Coaxial EC with Ibuprofen
Figure 23: The left image shows the particles obtained from a monoaxial electrospray experi-
ment done with a 0.064 gml−1 EC concentration in ethanol. The right shows the
crystals obtained when electrospraying coaxial with the same EC concentration for
the shell and an Ibuprofen concentration of 0.2 gml−1 in ethanol.
(a) Coaxial 0.1 gml−1 EC with Ibuprofen in
ethanol
(b) Coaxial 0.15 gml−1 EC with Ibuprofen in
ethanol
Figure 24: Difference of concentrations of ethyl cellulose during coaxial experiments. a.) Crys-
tals are formed and the grain boundary (black zigzag line) between two crystals can
be seen. b.) Sticky fibers have been formed with 0.15 gml−1 EC.
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three new parameter for the setup, with the ring diameter, the distance between ring and
nozzle and also the applied voltage of the ring. Furthermore no real improvement of
the results could be observed, so the ring was discarded for future experiments. The
other setup, that was tried, was not to spin on a charged alumina foil but into a small
metal dish filled with solvent. The first experiments were done with ethanol but the
issue here was, that the ethanol solved all the Ibuprofen from the beads and so it was not
possible to create coaxial beads. When using water instead of ethanol the beads would
stick together and build an uniform carpet like mat, so no beads and no fibers could be
observed. Also when connecting the high voltage supply source to the metal dish the
beads would be collected on the dish itself and not into the solvent. To prevent this a
small piece of alumina foil was put into the solvent as counter electrode but the problem
still was the same. The metal dish was also discarded as a result of these problems and
especially because of the problem of the solvent, in view of when working with differ-
ent polymers, that are soluble in different solvent, it is nearly impossible to find a suited
one.
Due to the forming of crystals and sticky fibers the usage of ethyl cellulose was
avoided for the further work and PVP, PVA and PCL as new polymers were used.
4.2.2. Coaxial experiments with PVP and Ibuprofen
The first coaxial experiments done with PVP as shell polymer had a mixed core from
ethyl cellulose and Ibuprofen. The concentration of the shell was 0.34 gml−1 in ethanol,
and the core had a 0.15 gml−1 ethyl cellulose and a 0.15 gml−1 Ibuprofen concentra-
tion in ethanol, respectively. Two different experiments were done with this setup with
different flow rates. Once the shell flow rate was 0.5ml h−1 and the core 0.3ml h−1 (ra-
tio 1:0.6), Figure 25a, and for the other the shell flow rate was 0.7ml h−1 and the core
flow rate 0.4ml h−1 (ratio 1:0.57), Figure 25b. Beads were formed on the fibers and as
seen in Figure 11 they are called beaded fibers or also beads on a string. Because the
characterization of such fibers can not be made easily the concenctration of PVP should
either be decreased or increased.
A decreasing of the concetration can be seen in Figure 25c and 25d. The beads are
now predominant and also have grown in size to a mean diameter of around 2 µm to
3 µm, but there are still some fibers on the beads. The shell flow rate for both of the
experiments were 0.8ml h−1 with a concentration of 0.31 gml−1 PVP and for the core
0.7ml h−1 with an applied voltage of −25 kV and a distance of 15 cm between the noz-
zle and the collector. The first experiment had a concentration of 0.1 gml−1 Ibuprofen,
for which the resulting beads can be seen in Figure 25c. The second experiment was
done with a concentration of 0.2 gml−1 Ibuprofen, the beads are depicted in Figure 25d.
Because of the fact, that one would want the drug loading of Ibuprofen into the
fibers as high as possible, different concentrations of Ibuprofen in ethanol were tried
out. 0.2 gml−1 and 0.25 gml−1 of Ibuprofen in ethanol could be spun but with higher
concentration the Ibuprofen would crystallize as soon as it would met a suitable start-
ing point, which there are many in the whole coaxial setup. So the maximal Ibuprofen
concentration used for the further experiments was 0.25 gml−1.
An increasing of the shell concentration of PVP leads to fibers, for which the diam-
eter can be chosen according to the used concentration, as shown in chapter 4.1.2 with
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(a) Shell: 0.4 gml−1 PVP in EtOH
Core: 0.15 gml−1 EC and 0.1 gml−1 Ibu
in EtOH
(b) Shell: 0.34 gml−1 PVP in EtOH
Core: 0.15 gml−1 EC and 0.1 gml−1 Ibu
in EtOH
(c) Shell: 0.31 gml−1 PVP in EtOH
Core: 0.1 gml−1 Ibu in EtOH
(d) Shell: 0.31 gml−1 PVP in EtOH
Core: 0.2 gml−1 Ibu in EtOH
Figure 25: Different fiber mats created with PVP and Ibuprofen from ethanol in a coaxial setup.
The difference between a.) and b.) is the change in the flow rates of the shell
and the core solutions. c.) and d.) show two different experiments with lower
PVP concentrations in ethanol and different Ibuprofen concentrations. The lower
concentrations of PVP results in electrospraying.
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the DOE. Image 26 shows a SEM image of a coaxial fiber mat made out of PVP and
Ibuprofen. The concentration used for PVP was 0.5 gml−1 and 0.2 gml−1 for Ibuprofen
both in ethanol, the flow rate for the shell was 1.2ml h−1 and for the core 0.5ml h−1,
the applied voltage was −20 kV and the distance between nozzle and the collector was
15 cm.
Figure 26: Coaxial fiber mat created with 0.5 gml−1 PVP in EtOH and 0.2 gml−1 Ibuprofen in
EtOH. The mean diameter of the fibers is 870 nm± 140 nm. The indicated numbers
are the diameters of the fibers in µm.
Due to the fiber mats produced with higher concentration could be handled with more
ease, comparing to the beads formed with lower concentrations, the further experiments
and also the release studies were conducted with PVP of higher concentrations. Some
experiments were also done with PVP of Mw of 1 300 000 Da, but the concentration
could not be high enough without the viscosity being already to high to handle for the
coaxial setup. For this reason the experiments were all continued with the Mw = 55 000
Da PVP.
An IR-spectrum of one of the coaxial fiber mats is plotted in Figure 27. All IR
spectra of the polymer used and also of Ibuprofen can be found in the appendix, chapter
E, Figure 45 to 48.
The spectra show, that both, PVP and Ibuprofen, can be found in the fiber mat. With
the IR it is not possible to know if the fibers are coaxial, but one can check, if both
components are in the fibers. With the small shoulders at 1726 cm−1, at 1512 cm−1 and
at 1439 cm−1 it is shown, that Ibuprofen can be found in the PVP fiber mats.
Also through calculation of the concentrations of the solution, 0.5 gml−1 PVP and
0.25 gml−1 Ibuprofen, and the flow rates, 0.7ml h−1 for the shell and 0.4ml h−1 for the
core, one can assume a drug loading of around 22.2 wt% of Ibuprofen in the fibers.
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Figure 27: IR-Spectrum of a coaxial fiber mat with PVP. Shoulders at 1726 cm−1, at 1512 cm−1
and at 1439 cm−1 indicates, that both components, PVP and Ibuprofen, can be found
in the mat.
4.2.3. Coaxial experiments with PVA and Ibuprofen
With the polymer PVA only coaxial experiments were done with the Sloviol 2 solution.
The resulting fibers are depicted in Figure 28 and were done with a shell flow rate of
0.45ml h−1 and a core flow rate of 0.5ml h−1 for a 0.25 gml−1 Ibuprofen concentration
in EtOH, the applied voltage was 20 kV and the distance was 15 cm. The experiments
with PVA were the only one done with a positive voltage, because PVA spins better with
a positive voltage.
Figure 28: Coaxial fiber mat created with 16 wt% PVA in water and 0.25 gml−1 Ibuprofen in
EtOH. The mean diameter of the fibers is 330 nm± 80 nm.
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The mean diameter of the created fibers were 330 nm± 80 nm. The drug loading of
Ibuprofen in the coaxial produced fiber mat should be 63.5 wt%, when calculating with
a shell concentration of 16 wt% PVA in water and a flow rate of 0.45ml h−1 and for the
core a concentration of 0.25 gml−1 Ibuprofen in ethanol and a flow rate of 0.5ml h−1.
The corresponding IR-spectrum of the coaxial fiber mat can be found in Figure 29
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Figure 29: IR-Spectrum of a coaxial fiber mat with PVA. The Ibuprofen in the fiber mats can be
seen at 1508 cm−1, at 1186 cm−1 and at 972 cm−1.
The small peaks at 1508 cm−1, at 1186 cm−1 and at 972 cm−1 indicate the existence
of Ibuprofen in the PVA fibers.
Because of the fact, that PVA should be spun in positive mode and PVP and PCL in
negative, no blend could be tried out. The blend was only done with PCL and PVP as
will be discussed in the next chapter.
4.2.4. Coaxial experiments with PCL and Ibuprofen
Due to PCL being not soluble in ethanol and Ibuprofen not soluble in acetic acid or
chloroform the system PCL-Ibuprofen showed the best results when doing coaxial elec-
trospinning [20,22,117,118]. This ensures, that the core and the shell components would be
located in the solvent that they are first solved in and thus being separated from one
another [80].
The first coaxial experiment done with PCL and Ibuprofen was with a 0.15 gml−1
solution of PCL in acetic acid and 0.2 gml−1 of Ibuprofen in ethanol. Because of the
sticky fibers, which occurred when spinning in acetic acid, as seen in the SEM image
a.) of Figure 20, the dish was used to collect the fibers. But the problem with the dish
was, that if ethanol is used, the Ibuprofen is solved into it and no Ibuprofen could be
found in the fibers, and if water is used, the PCL fibers would stick more together than
without the dish. So again, the dish was removed from the setup and only the alumina
foil was used as detector.
When using an acetic acid solution with a 0.2 gml−1 PCL concentration and an
ethanol solution with a 0.2 gml−1 Ibuprofen concentration for a new coaxial experi-
ment the result was a mixture between nanoparticles and -fibers as shown in Figure
30. The flow rates were the ones that were found to be optimal in the previous chapter
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1.65ml h−1 for the shell and 0.75ml h−1 for the core. The distance and the voltage were
also the same as before.
Figure 30: SEM images of coaxial electrospun fibers with a PCL concentration of 0.2 gml−1 in
acetic acid as shell and an Ibuprofen concentration of 0.2 gml−1 in ethanol as core.
Figure 30 shows, that both particles and fibers were collected in the coaxial experi-
ments. Because of the fact, that such a system is difficult to describe, the solvent or the
concentration of the shell had to be adjusted.
The corresponding IR-spectrum of this experiment is plotted in Figure 31. Because
most of the peaks from the Ibuprofen spectrum are hidden under the PCL spectrum,
only the peak at 1510 cm−1 shows that Ibuprofen can be found in the coaxial fiber mat.
According to the flow rates and the concentration the drug loading in these fibers is 25
wt%.
After the first coaxial experiment done with PCL, four different PCL concentrations
were spun with Ibuprofen to test the different release rates according to the concentra-
tions of the PCL in the fibers. For this PCL concentrations of 0.1 gml−1, 0.15 gml−1,
0.2 gml−1 and 0.25 gml−1 were solved in chloroform and then spun in the coaxial setup
with 0.25 gml−1 of Ibuprofen in ethanol. The SEM images of the four different experi-
ments can be seen in Figure 32. The lower two concentrations showed no fibers on the
SEM but the last two had fibers and also particles.
The drug loadings for these experiments ranged from 53wt% for the lowest concen-
trations to 31 wt% for the highest. The drug loading on these experiment were the
highest in all the experiments done due to the low concentration of PCL needed for the
setup to work, in comparison to the 0.5 gml−1 of PVP.
The last coaxial experiments that were conducted were blends of PCL and PVP. For
this the shell was PCL solved in chloroform and the core was a mixture of PVP and
Ibuprofen solved in ethanol. Like before the same four different concentrations of PCL
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Figure 31: IR-spectrum of the PCL-Ibuprofen coaxial nanoparticles and -fibers. The small peak
at 1510 cm−1 indicates that Ibuprofen can be found in the nanoparticles and fibers.
Figure 32: SEM images of coaxial experiments with different PCL concentrations 0.1 gml−1,
0.15 gml−1, 0.2 gml−1 and 0.25 gml−1 in chloroform as shell and a core of
0.25 gml−1 of Ibuprofen in ethanol.
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were used and for all experiments the same PVP and Ibuprofen concentrations in ethanol
were employed, 0.5 gml−1 and 0.25 gml−1, respectively. The flow rates of shell and
core were also the same as the ones optimized, 1.65ml h−1 for the shell and 0.75ml h−1
for the core, with a applied voltage of −20 kV and a distance of 15 cm.
The IR-spectrum of the experiment done with 0.15 gml−1 PCL in chloroform as shell
solution and 0.5 gml−1 PVP and 0.25 gml−1 Ibuprofen in ethanol as core solution is
plotted in Figure 33.
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Figure 33: IR-spectrum of a coaxial fiber mat with 0.15 gml−1 PCL as shell and 0.5 gml−1
PVP and 0.25 gml−1 Ibuprofen in ethanol as core. The double peak at 1722 cm−1
and 1653 cm−1 shows clearly both polymers and the shoulder at 1510 cm−1 shows
the Ibuprofen in the fibers.
The IR-spectrum shows that all three components can be found in the fibers. For
PCL and PVP the double peak at 1722 cm−1 and 1653 cm−1 shows that both polymers
are in the fibers. The size of the double peak is also relative to the ratio between both
concentrations, as will be shown later on. The shoulder at 1510 cm−1 indicates again
that Ibuprofen is in the nanofibers. The drug loadings for these four experiments ranged
from 19 wt% to 26 wt%, which is lower than the experiments done before, due to fact
that the PVP is also encapsulated in the PCL fibers.
Figure 34 shows the ratio between the PCL peak in the IR-spectrum at 1722 cm−1 and
the PVP peak at 1653 cm−1 plotted against the PCL concentration. A linear correlation
can be seen between the ratio and the concentration.
Because the core is soluble in ethanol, the produced fibers were put in a ethanol
solution after the spinning and after letting the fibers 24 h in the solution a new IR-
spectrum and new SEM images were taken of the fibers. The IR-spectra are shown in
Figure 35 and the SEM images are depicted in Figure 36.
The IR-spectrum shows that after 24 h only PCL is left in the fibers. The dotted line
is the same spectrum as was already shown in Figure 33, where also PVP and Ibuprofen
can be seen. But after the fibers were put in ethanol only the absorbances from PCL
were detected in the IR. This shows, that the PVP and the Ibuprofen can be taken out of
the fibers without destroying the PCL fibers. To demonstrate the fact, that the the fiber
structure were not completely destroyed a SEM image was taken, Figure 36.
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Figure 34: Correlation of the ratio between the concentration of PVP and PCL versus the PCL
concentration. A linear correlation can be seen.
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Figure 35: IR-Spectrum of a coaxial fiber mat with a PCL PVP blend after 24 h in ethanol. The
spectrum from Figure 33 is shown in a dotted line and after 24 h in ethanol the drawn
through line spectra shows that only PCL is left in the fibers.
Figure 36: SEM images from PCL PVP blend fibers before and after 24 h in ethanol. In the
right image the fibers seemed to have collapsed after the PVP-Ibuprofen core was
dissolved.
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The SEM image in the left shows the coaxial fiber mat before putting it in ethanol
over 24 h and the fibers have a round geometry as expected. The right images shows
the same fiber mat after 24 h in ethanol and the fibers seemed to have collapsed in the
vacuum. This is because the PVP and Ibuprofen core is not in the fibers and the PCL
fibers were hollow and then collapsed.
Figure 37: Cross section of coaxial electrospun fibers with a shell of 0.15 gml−1 PCL in chlo-
roform with a core of 0.25 gml−1 Ibuprofen in ethanol. It is unclear, if the difference
in the contrast between the shell (H) and the core (N) comes from coaxial fibers or
is only from a different angle.
While the SEM revealed the morphology and the size of the fibers and the IR could
determine the composition of the fibers, both methods are unsuited to prove the core-
shell architecture of the fibers. In order to do so, cross sections of the fibers were made
in different manners and Raman spectroscopy was used. Or in other words, as de Saint-
Exupéry [6] has said, "It is only with the heart that one can see rightly, what is essential
is invisible to the eye". One approach was to glue the fibers together and then cut them
with either scissors or with a razor blade. Another approach was to cut the fibers or rip
them apart after putting them in liquid nitrogen to freeze the fibers and the last one was
to use a cryostat microtom to cut the fibers. The cross section received are shown in
Figure 37.
The statement "the fibers are coaxial" can not be said with 100% certainty, when
seeing the images of the cross sections. The small images in the corner show a small
difference between the core and the shell of the polymer. This difference can either
come from a difference in morphology for the nanofibers on the surface and in the core
or it can come from coaxial fibers.
With the help of Raman spectroscopy cross sections of the fibers according to their
composition could be made. Figure 38 was taken with fibers made out of a PCL shell
and a core of Ibuprofen and PVP.
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Figure 38: Raman intensity images of a coaxial fiber with a PCL shell and an Ibuprofen in
PVP core. The last image shows a falsified color composition with PCL in red and
PVP/Ibuprofen in blue
As can be seen in the Raman images, the shell and the core are spatially separated.
The Ibuprofen and the PVP are also occupying the same space, which is also according
to the expectations. But the falsified color composition does not represent the desired
coaxial architecture, due to the fact, that the PCL (red) is located in the core and the
PVP and Ibuprofen (blue) are located in the shell.
This can come from a change of phase during the electrospinning, due to the fact, that
ethanol, the solvent used for the core, is more polar than chloroform, the solvent used
for the shell. Thus it is possible, that the core polymer and Ibuprofen will be transported
with the ethanol to the surface of the coaxial fibers. Even though a similar system
as described, polar protic solvent, water, in the core and chloroform in the shell was
already done in the literature [119,120]. The core-shell architecture for those fibers were
proven with transmission electron microscopy (TEM), differential scanning calorimetry
(DSC) and a slower release of the encapsulated drug in comparison to the free drug. It
is also possible, that the Raman did not cut through one fiber, but through three with
different compositions, or another possibility is that all the three fibers are connected in
a two-phase fiber.
One possibility to increase the probability of getting a cross section in the SEM and
also the Raman would be to spin the fibers onto a rotating drum and with this setup to
get linear aligned fibers instead of a chaotic deposition of the fibers onto the alumina
foil. With linear aligned fibers the cut through the fibers would have a higher probability
of cutting perpendicular to the fibers.
Another way to analyze the architecture of the fibers would be with the help of either
a TEM or with fluorescence, both methods have not been done during this thesis.
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4.3. Release Studies
For the analysis of the release of Ibuprofen from the produced fiber mats four different
release studies were done during the thesis according to the procedure explained in
chapter 3.3.2 with the help of the Pharmaceutical Technology and Pharmacology group
of the ICBT, especially with the support of Christa Ziegler-Meyer and Andrea Bayer:
1. Coaxial fiber mat with a PCL shell and an Ibuprofen core and a commercially
available Ibuprofen tablet for validation of the release setup and the production of
coaxial fiber mats.
2. Coaxial fiber mats with a PCL shell and an Ibuprofen core and with a PVA shell
and an Ibuprofen core for release tailoring of different polymers.
3. Coaxial fiber mats with a shell made out of four different PCL concentrations and
an Ibuprofen core for concentration dependent release rates.
4. Coaxial fiber mats with a shell made out of four different PCL concentrations and
an Ibuprofen - PVP core for concentration dependent release rates with coaxial
fiber mat produced from two polymers.
All release studies were done as described in chapter 3.3.2 using baskets for the fiber
mats.
The first release study was a comparison of the produced fiber mats and a commercially
available Ibuprofen tablet. The tablet was also used as reference to check if the setup
works as planned. As can be seen in Figure 39 and also in Table 9 the Ibuprofen was
released from the PCL fiber mat.
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Figure 39: First release study with a coaxial fiber mat with a PCL shell and an Ibuprofen core
and a commercially available Ibuprofen tablet. The tablet release the Ibuprofen as
fast as than the coaxial fibers.
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The fibers releases the Ibuprofen nearly as fast as the tablet, already after 1 h, Q1 h,
the fibers released 83% of the Ibuprofen in comparison to 85% for the tablet. The fibers
show a good encapsulation and releasing efficiency with releasing 99.4% of the calcu-
lated initial Ibuprofen amount after the measured 57 h. The first release study showed,
that it is possible to encapsulate as well as to release the Ibuprofen afterward from the
fibers.
In the second release study, two different polymers were compared, PVA and PCL. The
PCL coaxial fiber mat had a core concentration of 0.2 gml−1 Ibuprofen in ethanol, the
PVA a core concentration of 0.25 gml−1 of Ibuprofen in ethanol and the release study
was conducted over 7 h. The time was reduced from the last release study, because, as
can be seen in Figure 39 the maximal released amount was already achieved after a few
hours.
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Figure 40: Second release study with a coaxial fiber mat with a PCL shell and an Ibuprofen core
and with a fiber mat with a PVA core. The PVA fibers have a higher burst release but
also a lower encapsulation efficiency.
The PVA has a higher burst release of the Ibuprofen, but the PCL releases more
Ibuprofen after the 7 h. The faster burst release can be explained through the solubility
of PVA in water, which means, that once the fibers are in the PBS solution the fibers are
dissolved and so the Ibuprofen is faster available than with the PCL fibers. But the en-
capsulation efficiency is lower with the PVA fibers than with the PCL fibers, with only
22.7% for PVA and 81.9% for the PCL, which is lower than would have been expected
after the first release study. The low encapsulation efficiency of PVA can be explained
through the effect, that both, PVA and Ibuprofen are not soluble in the other solvent and
that at the tip of the coaxial nozzle a precipitation of Ibuprofen and PVA could be found
which decreases the encapsulation efficiency [121]. The slower release rate for PCL in
comparison to the first release study can come from different effects. Because of the
fact, that both experiments were done with the same solution but at different times, the
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second experiment could have a change in conductivity due to evaporation of the solvent
and thus have an effect on the process [66]. The difference can also be seen in Table 9 as
the first experiment gave fibers and the second gave beaded fibers.
For the third release study the effect on the PCL concentration for the shell was investi-
gated. For this four different concentrations of PCL were prepared, as before 0.1 gml−1,
0.15 gml−1, 0.2 gml−1 and 0.25 gml−1 of PCL in chloroform. As core solution the
Ibuprofen concentration was increased from 0.2 gml−1 to 0.25 gml−1 in ethanol, and
the other coaxial setup parameter were already listed in the chapter before. The release
profile of the four different coaxial fiber mats are plotted in Figure 41.
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Figure 41: Third release study with four coaxial fiber mats with a shell made out of different
PCL concentrations and an Ibuprofen core. The differences in the release rates are
not according to their concentration.
The release of the Ibuprofen from the four different concentrations of PCL were not
according to their concentrations and as expected. The release rate of the lower two
concentrations are almost identical, as can be seen with the calculated values in Table 9.
The release profile of the highest concentration of PCL, 0.25 gml−1, is the fastest, which
is not according to the literature [96]. The reason for this discrepancy could be the large
difference in viscosity of the shell and the core solutions. The shell solution, 0.25 gml−1
PCL in chloroform, has a high viscosity and the core solution, 0.25 gml−1 Ibuprofen in
ethanol, has a low viscosity, which could lead to an unknown process during the fiber
production.
The unknown process and differences in flow rates from the syringe pump to the ef-
fective flow rate on the output of the coaxial nozzle could also lead to the values above
100%. The release study showed that already after 10 h the maximal amount of Ibupro-
fen was released from the PCL fibers and that, except for the 0.2 gml−1 PCL fibers, all
of the calculated Ibuprofen was encapsulated and also released from the fibers.
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The last release study was done with four different concentrations of PCL in the shell
and all with the same core, an ethanol solution with 0.25 gml−1 of Ibuprofen and
0.5 gml−1 of PVP. To the four coaxial fiber mats one with a PVP shell and an Ibuprofen
core was added to analyze. All three release studies before were analyzed with UV-VIS,
but because PVP has a strong absorbance signal at 220 nm, for this study the analysis
was done with HPLC. The Ibuprofen peak came after 7.3min and with the help of the
calibration curve, Figure 13, the concentration could then be calculated from the peak,
the same goes for the UV measurement in the previous release studies.
The release profiles, with a total measuring time of 20 h, for the five different coaxial
fiber mats are depicted in Figure 42. For this release study the total time of 20 h seemed
to be to short, as the curves for the PVP and the two lower concentrations still show a
increase of the concentration curve. This indicates, that the PVP has a negative effect
on the release velocity of Ibuprofen from the fibers.
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Figure 42: Fourth release study with four coaxial fiber mats with a shell made out of different
PCL concentrations and a core made out of Ibuprofen and PVP and a fiber mat with
a PVP shell and an Ibuprofen core. The PVP in the core changes the release rate in
comparison to release study no 3.
For the highest concentration the same release profile is shown as in the release study
no 3, so there seems to be a effect that changes the coaxial procedure when spinning
with the highest concentration of PCL. And the change in concentration has still not the
anticipated influence on the release profile, as the one with higher concentrations show
a faster release as the one with the lower. The encapsulation efficiency lies for all four
fiber mats between 77% and 89%, which shows again, that it is even possible to spin the
Ibuprofen with PVP in the core and that the release of the Ibuprofen is still possible.
The two lower concentrations of PCL (0.1 gml−1 and 0.15 gml−1) and the PVP fibers
show a slower release as the ones only with PCL or with PVA. With this effect, the
release of Ibuprofen can be tailored to the desired release profile. The slower release
can be seen, when comparing the release profile or also when comparing the t25% and
the t50% values in Table 9.
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The slower release of PVP in comparison to PCL is not according to the solubility
of both polymers, as PVP is water soluble but PCL is not. But taking the findings of
the Raman into account, that it is possible that a phase change can occur, when working
with chloroform as shell solvent for PCL and ethanol for the core solvent for Ibuprofen
and PVP, a possible explanation can be found. So it is possible, that the Ibuprofen is
located at the shell of the coaxial PCL fibers but in the core of the coaxial PVP fibers,
and so the Ibuprofen would be released slower from the PVP fibers.
For the calculation of the therapeutic window some parameter had to be defined first.
The half life of Ibuprofen in the human body was found to be t1/2 = 2h [5] and the
volume for the blood in a human body was 5 l [122]. Furthermore the kinetic of the
degradation of Ibuprofen in the human body was assumed to be of first order, so the
concentration was calculated according to following equation:
N(t) = N0 · exp (−t/τ) (4)
With N0 being the start concentration of Ibuprofen and τ = t1/2/ ln(2) is the mean
lifetime. Figure 43 shows the time dependent behavior of the concentration in the human
body for a 400mg Ibuprofen tablet when administering the tablet every 8 h over the
course of 20 h. The therapeutic window between 150 µmol l−1 and 300 µmol l−1 is only
reached for a short period of time, 2.5 h, per tablet.
Figure 43: Therapeutic window of Ibuprofen for a tablet, the therapeutic window (green) is only
reached for short periods of time, figure reproduced from Brune et al. [5].
In comparison to this, the therapeutic window of the produced PCL fibers from re-
lease study no 4 shows a wider distribution of the Ibuprofen in the human body, as is
shown in Figure 44. The fiber releases enough Ibuprofen over a period of 8 h to reach
the therapeutic window and during this time also no overdose is achieved, as happens in
the first hour of the tablet. For this reason the fibers give a better release profile, which
also leads to fewer side effects.
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Figure 44: Therapeutic window of Ibuprofen for PCL coaxial fibers with a PVP and Ibuprofen
core, the therapeutic window (green) is reached over a period of 8 h and no overdos-
ing is achieved.
In the appendix, chapter E, in Figure 49 the time dependent behavior of the tablet,
the PCL fibers, the PVA fibers and the PVP fibers is shown. For the fibers to reach the
therapeutic window, the patient would have to take 400mg of the PCL fibers or 450mg
of the PVP fibers, which results in a Ibuprofen amount of approximately 100mg, or
350mg of the PVA fibers, which would result in a Ibuprofen amount of 50mg. The
PVA fibers have the shortest therapeutic window, nearly the same as the tablet, but the
PCL fibers and the PVP fibers show a release of Ibuprofen in the therapeutic window
over a time span of 8 h to 10 h.
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Table 9: The results of all the release studies conducted during the thesis. The values are explained in chapter 3.3.2. The first column indicates the
number of the experiment for better reference in the discussion.
Exp. No Shell Core Drug loading Q5min Q1 h Q50% Q100% t25% / min t50% / min Fiber-∅ (nm)
1 PCL 0.2 gml−1 in acetic acid Ibuprofen 0.2 gml−1 in EtOH 25 % 20.4% 83.3% 99.4% 99.4% 6 12 1360± 520
Ibuprofen Tablet (200mg) - 27.4% 94.9% 98.9% 98.9% 6 12 -
2 PCL 0.2 gml−1 in acetic acid Ibuprofen 0.2 gml−1 in EtOH 25 % 10.1% 52.7% 79.5% 81.9% 18 54 a
PVA 16 wt% in water Ibuprofen 0.2 gml−1 in EtOH 63.5% 3.4% 19.9% 22.7% 22.7% - - 350± 100
3 PCL 0.1 gml−1 in CHCl3 Ibuprofen 0.25 gml−1 in EtOH 53.2% 15.9% 74.9% 110.3% 110.3% 12 30 b
PCL 0.15 gml−1 in CHCl3 Ibuprofen 0.25 gml−1 in EtOH 43.1% 18.7% 76.2% 109.2% 109.2% 12 30 b
PCL 0.2 gml−1 in CHCl3 Ibuprofen 0.25 gml−1 in EtOH 36.2% 18.0% 66.3% 95.1% 95.1% 12 36 240± 80
PCL 0.25 gml−1 in CHCl3 Ibuprofen 0.25 gml−1 in EtOH 31.3% 35.1% 105.5% 110.6% 110.6% 6 12 200± 40
4 PCL 0.1 gml−1 in CHCl3 Ibuprofen 0.25 gml−1, PVP 0.5 gml−1 in EtOH 25.7% 12.7% 28.9% 75.9% 78.8% 48 168 870± 440
PCL 0.15 gml−1 in CHCl3 Ibuprofen 0.25 gml−1, PVP 0.5 gml−1 in EtOH 23.1% 13.4% 26.3% 77.6% 85.2% 54 198 2490± 1370
PCL 0.2 gml−1 in CHCl3 Ibuprofen 0.25 gml−1, PVP 0.5 gml−1 in EtOH 21 % 14.7% 44.5% 88.8% 89.0% 24 72 1090± 380
PCL 0.25 gml−1 in CHCl3 Ibuprofen 0.25 gml−1, PVP 0.5 gml−1 in EtOH 19.2% 33.3% 76.6% 77.0% 77.0% 6 12 3490± 2780
PVP 0.5 gml−1 in EtOH Ibuprofen 0.25 gml−1 in EtOH 22.2% 10.4% 28.4% 97.3% 106.5% 48 144 1360± 330
a Beaded fibers, b No fibers observed.
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5. Conclusion & Outlook
The produced coaxial fiber mats during this thesis and the release studies done with
those, showed that it is possible to encapsulate Ibuprofen and also to release it again
from the polymer fibers in a higher concentration as was done in the literature. In
the discussed literature from chapter 2.2.3 the drug loading often achieved small one-
digit percentage, whereas in this thesis drug loading up to 53 wt% were achieved for
Ibuprofen in a 0.1 gml−1 PCL shell and a mean drug loading of 30 wt% over all coaxial
fiber mats produced. Also the encapsulation and releasing efficiency was for most of
the fibers between 80% and 100% of the calculated concentrations. Furthermore the
change between the three polymers could be done without problems and with the same
setup, only the flow rate had to be adjusted according to the polymer to get the most
stable cone jets. The best setup for producing coaxial fibers was with a shell made
of a 0.15 gml−1 PCL concentration in chloroform and a core made of a 0.25 gml−1
Ibuprofen and 0.5 gml−1 PVP (Mw =55 000 Da) concentration in ethanol. The flow
rates for the shell and the core were 1.65ml h−1 and 0.75ml h−1, respectively. The
distance between the nozzle and the collector was 15 cm and the applied high voltage
was −20 kV.
It was also shown, that when changing the polymer, the release rate can be adjusted
according to the desired release of the drug into the human body. PVA showed to be
suitable for a fast release of the drug, whereas PVP slows the release down, leading to
a broader release profile. Unfortunately the concentration dependency of the concentra-
tion of the shell polymer on the release rate could not be shown for PCL, as was tried
out twice with different setups. For this either new experiments with PCL had to be
conducted or else with different concentrations of one of the other polymers, PVP or
PVA.
Even though the Raman showed, that the fibers are coaxial, the core and the shell
seemed to be interchanged, possibly due to a difference in the polarizability of the sol-
vents, ethanol and chloroform. The concentration dependent release studies of PCL
seemed to support this hypothesis, because if PCL is in the core and Ibuprofen or
Ibuprofen-PVP in the shell there would not be a big difference in the release rate ac-
cording to the concentration, at most inversely proportional, because the core would
have a bigger diameter and so the shell, when the concentration and the flow rate is
the same, a thinner mantle around the core. Whereas the dissolution of the PVP and
Ibuprofen from the coaxial fibers when putting them in ethanol for one day supports the
hypothesis, that the fibers have a PVP and Ibuprofen core and the resulting PCL fibers
are hollow and collapsed. Moreover the slower release of the release studies no 3 and 4
in comparison to the Ibuprofen tablet of release study no 1 also supports the Ibuprofen
core hypothesis. When comparing the release studies done in the literature with PCL
the hypothesis of a PCL core gets more support. Most of the release studies done with
PCL have release half times of the encapsulated drug of more than 10 h [79,119,120,123,124]
but nevertheless few of them showed a release half time of less than 10 h [95,99,102,104].
To proof one or the other hypothesis one would have to conduct further experiments
with ethanol and chloroform as solvent-systems for coaxial electrospinning and try to
make new coaxial fibers with concentration dependency, as already mentioned above.
For comparison of the cross sections it would be necessary to take SEM images of the
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monoxial fibers of the polymer to see if the change in morphology seen in Figure 37 is
from two different polymers in a core-shell architecture or if it is simply one polymer in
a crystalline and an amorph phase.
The release rate of the coaxial nanofibers made with a PVP shell and an Ibuprofen
core and the ones made with a PCL shell and a PVP and Ibuprofen core showed to be
suitable for a release of Ibuprofen in the therapeutic range over a time span of 8 h also
with a possible size and weight of the fiber mat being between 400mg to 500mg as this
is also the weight of commercially available tablets of Ibuprofen. To cover the first hour
after taking the fibers, one could combine the PCL fibers with the fast releasing PVA
fibers. With the right combination of the different fibers, one could tailor even more the
release profile.
This thesis showed that the encapsulation of Ibuprofen is possible and that it is also
possible to encapsulate Ibuprofen with another polymer into the core of a core-shell
nanofiber. As only three different polymers were tested in this thesis, more polymers
have to be tested and the release rates of the new fibers have to be compared to the
one already done. Also a coating of the fibers to make them more hydrophilic or hy-
drophobic can be tested to increase or decrease the release rate or a suitable coating to
ensure the maintaining of the core-shell architecture when passing through the acidic
environment of the stomach has to be tried out.
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Figure 45: IR spectra of Ibuprofen.
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Figure 46: IR spectra of PCL.
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Figure 47: IR spectra of PVA.
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Figure 48: IR spectra of PVP.
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Figure 49: Therapeutic window of Ibuprofen for PCL coaxial fibers with a PVP and Ibuprofen
core, the therapeutic window (green) is reached over a period of 8 h and no overdos-
ing is achieved.
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Introduction:
With the evolution of the high-trough-put screening 
(HTS) methods it is now possible to screen up to 100000 
pharmaceutical compounds each week and thus the 
amount of possible new active pharmaceutical ingre-
dients (API) growth every week[1,2]. Because of the fact 
that nearly half of the new API found today with the help 
of HTS have a low water solubility, electrohydrodynamic 
atomization (EHDA) can help to encapsulate these drug 
for better bioavailability[3,4].
As model drug Ibuprofen was used in this thesis, becau-
se Ibuprofen is one of the most used non-steroidal 
anti-inflammatory drug (NSAID) and has a low water-
solubility. To enhance the bioavailability of Ibuprofen an 
encapsulation of it into nanoparticles and -fibers with 
core-shell architecture was done and the encapsulation 
and releasing efficiency was researched.
Coaxial Setup:
Three different polymer, poly(e-caprolactone) (PCL), po-
ly(vinyl alcohol) (PVA) and poly(vinylpyrrolidone) (PVP), 
were used to encapsulate Ibuprofen into coaxial nano-
fibers.
For this a coaxial setup was used, as shown in figure 
1. The setup consists of a high 
voltage supply, a syringe pump, 
a syringe pump, a nozzle and a 
collector. The nozzle used vor 
the prodution of nanofibers was 
a coaxial nozzle, consisting of 
to inputs for the polymer solutions. The applied voltage 
was -20 kV and the distance between the nozzle and 
the collector 15cm. The fibers were then measured with 
SEM and the release of Ibuprofen was measured with 
the help of release studies.
Fig 1: Coaxial setup for the production of 
nanofibers with a core-shell architecture[5].
Conclusion:
In the found literature drug loading often achieved 
small one-digit percentage, whereas in this thesis drug 
loading up to 53% were achieved for Ibuprofen. 
Also the encapsulation and releasing efficiency was 
for most of the fibers between 80% and 100% of the 
calculated concentrations.
Results:
Table 1 shows the results achieved with the help of re-
lease studies. The PVA was the polymer with the fastest 
drug releasing rate of the three polymer.  
Polymer Drug loading Drug released
PVA, 16 wt% in H
2
O 25% 58%
PVP, 0.5 g ml-1 in EtOH 22% 100%
PCL, 0.15 g ml-1 in CHCl
3
1 43% 100%
PCL, 0.15 g ml-1 in CHCl
3
2 26% 85%
The release profil of a coaxial fiber mat with a 0.1 g ml-1 
PCL in CHCl
3
 shell 
and a 0.25 g ml-1 
Ibuprofen and 0.5 
g ml-1 PVP core in 
ethanol is plotted 
in figure 2. The 
release of Ibupro-
fen was meaured 
over a time span of 20 hours, and 80% of the theoreti-
cal Ibuprofen amount 
was released.
With the PCL fibers 
and the PVP fibers one 
could achieve a cover-
ing of the therapeutical 
window of Ibuprofen 
over a time span of 8 
h, in comparison to 2 h 
with commercially available tablets, as is shown in fig 3[6].
Table 1: Four different coaxial fibers with their drug loading and drug releasing efficiency. 
1: Ibuprofen core, 2: PVP and Iburpofen core.
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Fig 3: Release profile of a PCL:PVP-Ibuprofen coaxial fiber mat.
 Fig 4: Comparison between the therapeutical window of   
 the fibers and a tablet[6].
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